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CHAPTER I 
 
INTRODUCTION 
 
The Perinatal Heart and the Cardiac Action Potential  
 The cardiac action potential is an essential physiological event that enables rapid 
changes in heart rate and is also a response to changes in autonomic tone. Propagation of an 
action potential by a single cardiac cell occurs through activation of multiple ionic currents 
mainly, sodium channels, potassium channels, and calcium channels in a specific sequence 
(Figure 1). The shape and duration of the action potential of the working myocardium is 
determined by multiple phases that correlate with specific ionic currents.1 Phase 4 is the 
resting membrane potential of the cardiac cell that is stabilized by inward rectifying potassium 
channels. The inwardly rectifying potassium channel (Kir2.x) subfamily members primarily 
mediate cardiac IK1, but other inward rectifiers may also be involved in cardiac excitability.2,3 
The resting membrane potential is typically -90 mV for healthy adult ventricular myocytes. The 
initial phase of the action potential, phase 0, is the rapid depolarization phase driven by an 
influx of sodium ions through voltage-gated sodium channels, primarily NaV1.5. Phase 1 is a 
phase of rapid repolarization when sodium channels are inactivated and there is activation of 
transient outward potassium currents (Ito). Phase 2 is the plateau phase that is due to the influx 
of calcium ions by L-type calcium channels (CaV1.2) balanced with outward potassium 
currents.1,4 The third phase of the action potential, phase 3, is the rapid repolarization that 
restores the membrane voltage back to resting potential.  
 2	  
 
Figure 1: The cardiac action potential.  
The phases of the action potential are labeled above as described in the text. The balance of 
inward and outward ionic currents is shown below the action potential. Currents are not drawn 
to scale. Figure adapted from Roden and George, Annu. Rev. Med. (1996).1 
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This phase is largely driven by voltage-gated potassium channels, KV11.1, also known as 
KCNH2 or hERG (IKr), and KV7.1, also known as KCNQ1 or KvLQT1 (IKs).4  
 Nodal “pacemaker” cells of the heart have a different action potential and resting 
membrane potential (-50 to -60 mV) compared to cardiac muscle cells. This is due to the rate 
of depolarization in phase 0 being much slower than that of working myocardial cells, resulting 
in slower propagation of the cardiac impulse in the nodal regions.4,5 The cardiac action 
potential configuration of the atria, ventricles, and nodal cells are heterogeneous, which is 
reflected by the different types of action potentials and ionic currents measured in isolated 
cardiomyocytes by electrophysiological recordings.1,5,6  
 The depolarization and repolarization phases of the action potential are reflected in the 
electrocardiogram (ECG). The ECG measures the electrical activity of the heart over a period 
of time. The average atrial depolarization (P wave) and ventricular repolarization (QT interval) 
duration is determined by the ECG. Abnormalities in heart rhythm are detected by the ECG 
and can result in reduced pumping efficiency of the heart muscle. The ECG cannot measure 
the pumping efficiency of the heart. Therefore it is measured by echocardiography (see 
Chapter II).4  
 Throughout the course of perinatal heart development, ion channel expression patterns 
are constantly changing which in turn alters the cardiac action potentials responsible for the 
rapid activation and repolarization of cardiac cells.7–10 It is important to understand some of the 
distinguishing features between the adult and fetal heart in order to determine the molecular 
mechanisms of perinatal cardiac arrhythmias. The fetal heart rate is significantly higher (120–
160 beats/min) than the adult heart rate (60–100 beats/min). In addition, the fetal myocardium 
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is also less compliant than the infant or adult heart and the cell capacitance (size) is reduced in 
the much smaller fetal heart.11   
 In development, the cardiac action potential duration (APD) has been shown to vary 
among fetal, neonatal, and adult cardiomyocytes in several experimental animal models.7–9,12 
The timing of the APD is crucial because as long as the ventricular tissue is depolarized it 
cannot be re-excited due to the unavailability of the voltage-gated sodium channels as 
discussed further below. This mechanism is cardioprotective against premature excitation and 
is an essential process required to maintain the proper timing between diastolic filling and 
ejection intervals by the heart.13 In the guinea pig, APDs at 50% and 90% repolarization have 
been shown to decrease between fetal and neonatal periods and later increase between the 
neonatal and adult periods. Additionally, there was no substantial age-related change in 
resting membrane potential or action potential overshoot reported.9 In fetal and neonatal rat 
heart, the duration of the ventricular and atrial action potentials was also inversely related to 
heart rate, and their rate sensitivity decreased with age.14 The changes observed for the APD 
between fetal and infant heart is due to developmental changes in the expression of ion 
channels.  
 In many animal model systems, changes in ion channel expression have been observed 
throughout development but there is very little evidence of those specific changes in human 
fetal and infant hearts.12 A study of murine embryonic development and ion channel function 
showed that sodium channel current density increases during murine embryogenesis and L-
type calcium activation plays a dominant role in depolarization at the earliest stages.15 In a 
large-scale analysis of ion channel gene expression in the mouse heart during perinatal 
development, investigators confirmed that mRNA expression of NaV1.5 was reduced in the 
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immature (fetal and neonatal) hearts compared to adult hearts. This study also found 
significant up-regulation of chloride channels in fetal and neonatal hearts compared to adult, 
especially chloride channels activated by intracellular calcium.16   
 A more recent study comparing neonatal and adult canine ventricular myocytes has 
shown that two major repolarizing potassium currents (IKs and Ito) are present in adult 
ventricular cells but these currents are absent in the 2-week-old neonate, which may contribute 
to the shortening of the APD after birth. They also showed that peak and late sodium currents 
are significantly smaller in the neonatal heart compared to adult.12 Therefore, the immature 
heart exhibits some major differences in ionic currents compared to the adult heart. These 
observations may have important implications when elucidating a molecular mechanism for 
perinatal cardiac arrhythmias. Further investigation of the developmental regulation of ion 
channels is required for a better understanding of disease pathogenesis in the earliest stages 
of life. 
 
Molecular Mechanisms of the Long-QT Syndrome 
 The long-QT syndrome (LQTS) occurs infrequently in the general population with a 
prevalence of approximately 1 in 2500 people.13,17 Patients with LQTS exhibit two diagnostic 
features that include prolongation of the heart rate–corrected QT interval (QTc ≥ 450 ms) and, 
in some cases, stress-induced syncope.13 In addition, severe life-threatening cardiac 
arrhythmias may occur such as ventricular fibrillation. Ventricular fibrillation can sometimes 
lead to a morphologically distinctive polymorphic tachycardia known as ‘torsades de pointes.’18 
The genetic basis of LQTS was identified in the mid-nineties and all the LQTS genes identified 
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so far encode cardiac ion channel subunits or proteins involved in modulating the previously 
described ionic currents (Figure 1). Mutations in ion channel genes cause the disease by 
prolonging the APD and subsequently ventricular repolarization.17  
 There are multiple subtypes of congenital LQTS based on the disease-associated 
genes. Type-1 LQTS (LQT1), is the most prevalent subtype with over 50% of cases caused by 
mutations in the gene KCNQ1 encoding the KV7.1 potassium channel.17 This channel is 
responsible for the slow component of the delayed rectifier repolarizing current (IKs) involved in 
phase 3 of the cardiac action potential.19,20 Therefore, a loss of function of KV7.1 results in a 
reduction in IKs and delays ventricular repolarization. Type-2 LQTS (LQT2) is prevalent in 
about 30% of genotyped patients and occurs as a result of mutations in KCNH2. The gene 
KCNH2 encodes the major repolarizing voltage-gated potassium channel, KV11.1, also known 
as human ether–a-go-go related gene (hERG). Loss of function mutations in hERG result in 
prolongation of APD and the QT interval.21 LQT1 patients typically exhibit a progressive QTc 
prolongation at higher heart rates or during exercise. By contrast, LQT2 patients typically 
demonstrate maximum QTc prolongation at submaximal heart rates with subsequent QTc 
correction toward baseline values at higher heart rates.22,23 Cardiac events in patients with 
LQT2 are predominately associated with sudden arousal.24  
 Mutations in the gene KCNE1 encoding KCNE1 protein has been associated with type-
5 LQTS (LQT5). KCNE1 is a potassium channel subunit that assembles with KV7.1 (KCNQ1) 
to produce the slow delayed rectifier IKs and may also assemble with hERG to modulate the 
rapid delayed rectifier IKr.25 In addition, mutations in the gene KCNE2 that encodes another 
auxiliary subunit of voltage-gated potassium channels is associated with type-6 LQTS (LQT6). 
Some mutations in KCNE1 or KCNE2 modulate voltage-gated potassium channel function that 
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reduces potassium currents (IKs or IKr) and results in a prolongation of ventricular 
repolarization.26,27  
 The combination of β-adrenergic receptor antagonists such as propranolol and an 
implanted cardioverter defibrillator (ICD) is a safe and reliable form of therapy for managing 
high-risk LQTS.28 The β1-adrenergic receptors (β-ARs) are G-protein coupled receptors 
expressed in cardiac tissue that upon activation are responsible for an increase in heart rate 
and cardiac contractility by a calcium dependent mechanism.29 In the case of LQT1 syndrome 
patients, β-blocker administration is thought to reduce incidence of cellular imbalance in 
response to stimulation of β-ARs, which occurs when one target of β-AR stimulation, the 
KCNQ1 channel, is eliminated from the cellular response.13 However, this treatment is also 
effective for other subtypes of LQTS to control heart rate. 
 Mutations in an integral membrane protein, ankyrin-2, have been associated with type-4 
LQTS (LQT4) likely because of the protein’s association with ion channels.17 A loss of function 
of ankyrin-2 results in disruption of the cellular organization of the sodium/potassium (Na+/K+) 
ATPase,30 the sodium/calcium (Na+/Ca2+) exchanger, and inositol-1,4,5-trisphosphate 
receptors. All of which are ankyrin-2-binding proteins. Ankyrin-2 loss of function reduces 
targeting of these proteins to the transverse tubules and reduces the overall protein level in 
cardiomyocytes. Ankyrin-2 mutations may also lead to altered calcium signaling in adult 
cardiomyocytes which provides insight to the molecular mechanism of LQT4.31 
 Calcium signaling is essential for many of the cellular processes within cardiomyocytes 
and many other cell types. Mutations in the gene CACNA1C encoding the L-type calcium 
channel, CaV1.2, are associated with type-8 LQTS (LQT8 or Timothy syndrome).17 Timothy 
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syndrome is a rare autosomal dominant disorder characterized by physical malformations, QT-
prolongation and arrhythmias, as well as neurological and developmental defects. This 
syndrome is a result of a gain of function of L-type calcium channels that disrupts cellular 
calcium homeostasis.32 The most common biophysical defect associated with LQT8 is loss of 
calcium-dependent inactivation (CDI) of the L-type calcium channels (see Chapter IV).33,34  
 An autosomal dominant disorder, Anderson-Tawil syndrome or LQT7, is associated with 
mutations in KCNJ2 that encodes an inwardly rectifying potassium channel, Kir2.1.13,17 
Anderson-Tawil syndrome is characterized by QT prolongation as well as periodic paralysis 
and skeletal developmental abnormalities. Kir2.1 is responsible for maintenance of the resting 
membrane potential of cardiac and skeletal muscle cells. The mutations that were discovered 
in association with this disease have been shown to exhibit a loss of Kir2.1 function which may 
contribute to arrhythmogenesis.35  
 Another subtype of LQTS, LQT9, is associated with mutations in caveolin-3 encoded by 
the gene CAV3.17 Caveolin-3 is the major scaffolding protein of cardiac caveolae and has been 
associated with skeletal muscle disease, cardiomyopathy, and LQT9. It is proposed that 
caveolin-3 co-immunoprecipitates with hERG channels.36 However, caveolin may participate in 
the scaffolding and trafficking of other ion channels important for cardiac repolarization.  
Reduced trafficking of ion channel proteins such as hERG results in loss of function of the 
potassium channels and prolongs ventricular repolarization. 
 In recent years, mutations in the gene SCN4B that encodes the β4 subunit responsible 
for modulating cardiac sodium channel gating have been discovered. These mutations are 
associated with LQT10. Four different beta-subunits have been described and all are 
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detectable in cardiac tissue. A mutation in the β4 subunit may lead to a gain of function of 
NaV1.5 that delays ventricular repolarization.37 Type-3 long QT syndrome (LQT3), which will be 
discussed further in the next section, is associated with mutations in SCN5A encoding the 
voltage-gated cardiac sodium channel (NaV1.5) and is prevalent among 10-15% of LQTS 
cases genotyped. Patients with LQT3 typically experience syncopal episodes during sleep or 
with slower heart rates. 24 
 In summary, there are multiple subtypes of LQTS that correspond to the genotype-
specific cause of the disease. Additionally, the molecular triggers for cardiac events in these 
patients also differ. There are many molecular mechanisms that may result in delayed 
ventricular repolarization, prolongation of the QT interval, and episodes of ventricular 
tachycardia.  Investigations into the clinical aspects and molecular mechanisms of LQTS have 
provided novel and important insight into the electrical activity of the human heart and how 
small disturbances in ion flow can have significant consequences for human disease.13  
 
Voltage-Gated Cardiac Sodium Channel Dysfunction and the Pathogenesis of LQT3 
 A variety of inherited human disorders affecting skeletal muscle contraction, heart 
rhythm, and nervous system function are caused by mutations in genes encoding voltage-
gated sodium channels. The gene SCN5A, located on the short arm of chromosome 3 at 
position 21, encodes the alpha (α) subunit of the voltage-gated cardiac sodium channel, 
NaV1.5 (Figure 2).38 The sodium current conducted by NaV1.5 is critical for the maintenance of 
impulse conduction in the heart and is responsible for the depolarizing phase of the cardiac 
action potential in the working myocardium (Figures 1 & 4).39 
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Figure 2: Topology diagram of the alpha subunit of the voltage-gated cardiac sodium 
channel.  
NaV1.5 consists of 4 domains with 6 trans-membrane regions. The S4 transmembrane region 
of each domain is a positively charged voltage sensor. The S5 and S6 transmembrane regions 
of each domain form an ion selective pore. The D3/D4 linker (shown in red) is required for the 
rapid inactivation of the sodium channel. Figure adapted from George, A. JCI (2005).38   
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 The cardiac voltage-gated sodium channel consists of four domains with six 
transmembrane-spanning regions.40 The S5 and S6 transmembrane regions form the ion 
selectivity pore while the S4 transmembrane region functions as the voltage sensor.41 Voltage-
gated sodium channel activation is elicited upon depolarization of membrane potential that 
leads to opening of the channel. Normally, activation of NaV1.5 is transient, owing to fast 
inactivation that is mediated by structures located on the cytoplasmic face of the channel 
protein, mainly the D3/D4 linker. The channels cannot open again until the membrane is 
repolarized and they undergo voltage-dependent recovery from inactivation.38 During the 
recovery from inactivation period, channels must deactivate or transition from the inactivated to 
the closed state.42   
 The three states of the ion channel (activation, inactivation, and closed) occur within a 
few milliseconds and are essential for the normal function and rapid gating of NaV1.5 (Figure 
3).38 The cardiac sodium channel is a multi-protein complex in which auxiliary proteins interact 
with the α-subunit to regulate its gating, cellular localization, intracellular transport, and 
degradation. These proteins include beta (β) subunits (1-4), calmodulin, protein kinases, 
phosphatases, and many others. These proteins also play important roles in the normal 
function and gating of the sodium channel (also see Chapter IV).43  
 Mutations in SCN5A are associated with sodium channel dysfunction that can result in 
life-threatening cardiac arrhythmias such as in LQTS.38 The major biophysical defect of NaV1.5 
that contributes to type-3 LQTS (LQT3) is persistent sodium current (INa) that is usually due to 
impaired inactivation of the channels (Figure 4).38 Persistent sodium currents lead to delayed 
ventricular repolarization and torsades de pointes.44 
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Figure 3: The three functional states of the voltage-gated cardiac sodium channel. 
Depolarization of the cellular membrane results in activation of voltage-gated sodium channels. 
This allows the influx of sodium current followed by a rapid inactivation of the channels. 
Sodium channels will remain in the closed state when the cell membrane is hyperpolarized. 
Figure adapted from George, A. JCI (2005).38     
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Figure 4: Persistent sodium current in the pathogenesis of LQTS. 
Persistent sodium current (INa) is the most common functional defect of the cardiac sodium 
channel associated with type-3 LQTS. Persistent sodium current prolongs ventricular 
repolarization and results in prolongation of the QT interval on the ECG. Figure adapted from 
George, A JCI (2005).38    
 
 
 
 
 14	  
 Severe arrhythmias, such as LQTS, typically present in early childhood or during 
adulthood, but in extreme cases may present during the perinatal period.45–47 A number of 
SCN5A mutations, many of which are de novo (not inherited), present with earlier onset and 
more severe congenital arrhythmia syndromes than is typical for LQTS.48–51 The reason for 
greater severity and lethality of certain genetic variants during early life is not well understood. 
 The major consequences of LQTS in fetal life include severe hydrops fetalis (edema) 
and intrauterine fetal demise.11,52–54 Clinical signs suggestive of fetal LQTS include ventricular 
tachycardia, second-degree atrioventricular (AV) block and, most commonly, sinus 
bradycardia.53 The term ‘2:1 AV block’ is defined by two P waves preceding 1 QRS wave on 
the ECG.60 This is due to the intermittent failure of AV conduction caused by sodium channel 
dysfunction.61 Unfortunately, such findings may go undetected due to the lack of routine 
electrocardiographic testing of fetuses.46  
 In developed countries, sudden infant death syndrome (SIDS) is the leading cause of 
death in the first year of life. SIDS is a diagnosis of exclusion when rigorous efforts to identify 
the cause of death are not revealing.46 The pathophysiological mechanisms of SIDS are poorly 
understood and current theories comprise a multitude of genetic and environmental factors 
that may contribute to its cause.55  
 An Italian study in which ECG-screening was performed on apparently healthy newborn 
infants revealed a prevalence of QTc prolongation (> 450 ms) of 1 in every 2534 live births.56 
Ion channel mutations have been discovered in approximately 10% of SIDS victims, 
implicating cardiac arrhythmias as a contributing factor to this tragic condition.57 Furthermore, 
approximately 5% of these cases are associated with mutations in SCN5A.58 Therefore, it is of 
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great importance to identify the preventable causes of sudden death in neonates for the 
effective diagnosis and preventative treatment. 
 
Genetic Studies of SCN5A Mutations and LQTS 
 Genetic studies have revealed numerous SCN5A mutations that cause voltage-gated 
sodium channel dysfunction associated with LQTS. In addition, cardiac arrhythmias are 
implicated as a contributing factor to cases of intrauterine fetal demise and SIDS.58 Previous 
studies of SIDS victims identified SCN5A rare variants F2004L and P2006A that are both 
located on the C-terminal tail of NaV1.5.56,59 These rare variants exhibited increased persistent 
sodium current resembling the biophysical defect observed for LQT3.58 Although SCN5A 
mutations associated with SIDS have been well characterized in the canonical form of 
NaV1.5,56,59 there still remains little evidence of the molecular mechanisms and molecular 
context that predispose to severe forms of LQTS and sudden death in the earliest stages of 
life.   
 Here we present the clinical background and the known molecular mechanisms of 
several SCN5A mutations investigated in our laboratory. In addition to the previous de novo 
SCN5A rare variants described, a mutation of alanine-1330 to glutamic acid (A1330D) was 
discovered in an Italian boy with early-onset LQTS. The proband, a Caucasian male, was 
delivered by Caesarean section at 33 weeks’ gestation because of oligohydramnios. On the 
second day of life, he exhibited bradycardia followed by an episode of ventricular fibrillation 
and he was successfully resuscitated (chest thump, defibrillation). The electrocardiogram 
revealed a prolonged QTc (500 msec) and 2:1 AV block. Echocardiography demonstrated 
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normal cardiac anatomy and function. Despite treatment with lidocaine, MgSO4, propranolol, 
and mexiletine, the subject continued to have frequent episodes of ventricular tachycardia, 
including torsades de pointes, and ventricular fibrillation prompting repeated external 
defibrillations. He died at age 70 days following a final episode of cardiac arrest.  
 The SCN5A-A1330D mutation affects the same residue as another de novo mutation 
(A1330P) associated with sudden cardiac death at age 9 weeks.45 These two mutations are 
located within D3 between S4 and S5 of NaV1.5 (Figure 5). Biophysical studies on A1330D 
and A1330P have shown that they both evoke a greater persistent sodium current compared 
with wild-type channels.45,62 
 The most severe cases of LQTS in early life that are associated with sodium channel 
dysfunction are typically de novo mutations; another example is F1473C. This phenylalanine-
1473 to cysteine mutation was discovered in a newborn infant with extreme QT prolongation of 
800ms, 2:1 AV block, and differential responses to treatment such as lidocaine. This mutation 
occurs within the inactivation gate or the D3/D4 linker of NaV1.5 (Figure 5). The D3/D4 linker is 
a highly conserved region of NaV1.5 and is essential for fast inactivation of the channel.63 
Biophysical studies of F1473C revealed multiple changes to sodium channel gating that could 
contribute to delayed ventricular repolarization such as persistent sodium current and a shift in 
the voltage-dependence of inactivation.48  
 Another novel de novo missense SCN5A mutation, R1623Q, was discovered in a 
Japanese infant girl with episodes of sporadic LQTS. This arginine-1623 to glutamine mutation 
is located in the S4 of D4 within NaV1.5 (Figure 5). In contrast to many other SCN5A mutations 
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Figure 5: SCN5A mutations associated with perinatal and typical onset LQTS. 
L409P and the common polymorphism R558 associated with LQTS of a 19-week fetus are 
shown in red. A1330D associated with perinatal LQTS and sudden death is shown in blue. 
F1473C associated with neonatal LQTS and fetal bradycardia is shown in purple. R1623Q 
associated with neonatal LQTS is shown in orange.  Deletion of 1505-1507 of KPQ residues 
(delKPQ) is shown in green. Figure adapted from George, A. JCI (2005).38  
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associated with LQTS, R1623Q does not evoke persistent sodium current. However, R1623Q 
increased the probability of long openings as shown through single-channel recordings. This 
mutation also caused early re-openings and a prolongation of inactivation kinetics.64 While 
these gating defects differ mechanistically from other SCN5A mutations associated with LQT3, 
slowed inactivation is another biophysical defect that also contributes to the pathogenesis of 
the disease. 
 In a rare case of an early-onset fetal arrhythmia, a de novo SCN5A mutation, L409P, 
was discovered. This leucine-409 to proline mutation was identified in a 19-week fetus with a 
severe case of LQTS, torsades de pointes, 2:1 AV block, and severe hydrops fetalis that 
resulted in termination of the pregnancy. This is the earliest known presentation of LQTS ever 
reported and the severity of the arrhythmia was profound. The fetus also demonstrated 
homozygosity for a common polymorphism H558R, also designated R558 (Figure 5).52,65 The 
SCN5A polymorphism, R558, is present in 20% of the Caucasian population and is also found 
in other ethnic backgrounds.66–70 In addition, R558 has been shown to potentiate dysfunction 
of other mutations in domain I of the sodium channel.71 Therefore, it is important to consider 
the additional effects of a common variant (R558) in combination with the L409P mutation (see 
Chapter II).  
  In contrast to the previous mutations described, genetic studies on LQTS have also 
revealed numerous SCN5A mutations that cause voltage-gated sodium channel dysfunction 
associated with a later or more typical presentation of the disease in early childhood or early 
adulthood. A very well studied mutation associated with ‘typical’ onset of LQTS is a deletion 
mutation of nine bases that code for lysine-1505, proline-1506, and glutamine-1507 (ΔKPQ or 
delKPQ) in the inactivation gate between D3 and D4 of NaV1.5 (Figure 5). NaV1.5-delKPQ 
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exhibits sustained inward sodium current that contributes to prolongation of the cardiac action 
potential leading to LQTS.72,73 However, this deletion is rarely reported in neonates and 
classically presents in adulthood74 but the underlying molecular mechanism of this later onset 
is unknown. These characteristics make delKPQ an interesting candidate to study as a strong 
comparison with mutations discovered in early life arrhythmias (see Chapter III).  
  There are more than 450 mutations in SCN5A that have been identified in patients with 
arrhythmia predisposition syndromes.75 In addition to mutations that result in LQT3, SCN5A 
mutations have been found to be associated with Brugada Syndrome,43,76 atrial 
fibrillation,68,77,78 conduction diseases,61,66 and dilated cardiomyopathy.79–81 Brugada Syndrome 
(BrS) is an inherited autosomal dominant arrhythmia characterized by right bundle branch 
block and prominent ST segment elevation on the ECG in addition to ventricular fibrillation.60 It 
is estimated that 20-25% of patients affected with BrS have mutations in SCN5A. In contrast to 
the mechanism of LQTS, SCN5A mutations associated with BrS result in a loss of function of 
NaV1.5. The biophysical defects associated with a loss of function of the cardiac sodium 
channel include a reduction in current density, defective trafficking of the channels, loss of 
channel availability, or faster channel inactivation.76 Furthermore, some SCN5A mutations are 
associated with a phenotypic overlap of BrS and LQTS (e.g. E1784K). These SCN5A 
mutations may evoke a persistent sodium current of NaV1.5 in addition to a reduction in current 
density or loss of channel availability.82  
  Although many SCN5A mutations associated with cardiac arrhythmias such as LQTS 
and BrS have been investigated, the molecular factors that predispose to sudden death during 
early life are still unknown. Therefore, we must also consider cellular processes that regulate 
gene expression such as alternative splicing. Variability in alternative splicing patterns of pre-
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mRNA is a major source of protein diversity in higher eukaryotes. The most common form of 
alternative pre-mRNA splicing is called exon skipping. In exon skipping, a particular exon may 
be included in mRNAs under some conditions or in particular tissues, and may be absent from 
the mRNA in others.83 Therefore we must consider the developmentally regulated alternative 
splicing mechanisms of ion channel genes that may contribute to the onset and severity of 
cardiac arrhythmias.  
 
Alternative Splicing of NaV1.5 
 The gene SCN5A that encodes the voltage-gated cardiac sodium channel consists of 28 
exons spanning approximately 80 kb on chromosome 3p21. There have been 10 different 
alpha subunits of the cardiac sodium channel cloned from different mammalian tissues. The 
protein diversity of the cardiac sodium channel is due to alternative splicing.84 In this cellular 
process, exons of a gene may be included or excluded from the final processed mRNA 
produced from that gene. When the protein is translated from different mRNAs, this results in 
changes in the amino acid sequence and subsequently alters the function of the protein.83,85 
Each splice variant of NaV1.5 has its own tissue specificity and function.  
 Previous studies have shown the presence of two wild-type splice variants, one with a 
glutamine residue at position 1077 (Q1077) and one lacking this glutamine (Q1077del) in 
human hearts. Quantitative mRNA analysis from human hearts showed that a shorter 2015 
amino acid splice variant lacking glutamine at position 1077 (Q1077del) made up ~65% of the 
transcript in every heart examined out of 200 samples. Age, sex, race, or structural heart 
disease did not affect the proportion of Q1077del. The only significant differences between 
Q1077 (hH1) and delQ1077 are that Q1077 exhibits a significantly hyperpolarized shift in the 
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voltage-dependence of inactivation and slower recovery from inactivation. In addition, the 
common polymorphism H558R (described previously) in combination with Q1077, results in a 
significant reduction in the sodium current density. A reduction in current density underlies the 
mechanism for BrS and conduction system disorders.69 Therefore, alternative splicing of 
NaV1.5 may contribute to cardiovascular disease risk in some individuals.  
 Heart failure has also shown to be associated with reductions in sodium current. Studies 
investigating the presence of NaV1.5 splice variants in heart failure have revealed three new 
mRNA splice variants in exon 28 designated as E28B (27 bp), E28C (39 bp), and E28D (114 
bp). Splice variants E28B, E28C, and E28D were shorter than the full-length mRNA transcript 
for NaV1.5 and were predicted to result in prematurely truncated sodium channel proteins 
missing the segments from domain IV, S3 or S4 to the C terminus. Individually, E28C and 
E28D do not exhibit sodium currents when expressed in heterologous cells. Quantitative real-
time RT-PCR experiments revealed that the relative abundances of each of the variants 
increased from fetal to adult heart, respectively. In addition, explanted ventricles from patients 
that suffered from heart failure exhibited a significant increase in E28C and E28D transcripts 
as well as a significant reduction in E28B and full-length transcripts. When E28C and E28D 
were co-expressed with WT NaV1.5 in heterologous cells, the splice variants suppressed 
sodium current density of the functional channels compared to over-expression of NaV1.5 
alone. Therefore, abnormal SCN5A splicing may contribute to reductions in sodium current in 
heart failure and may contribute to regulation of the developing heart.86,87 
 Fetal NaV1.5, previously known as NaV1.5e or neonatal NaV1.5,88 is another alternatively 
spliced voltage-gated sodium channel that contains an alternative exon 6 (designated here as 
exon 6A) in the mRNA transcript and results in translation of several residues within a voltage-
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sensor domain (D1/S3-S4) that differ from adult NaV1.5 (Figure 6). Exon 6A and exon 6 differ 
in 31 nucleotide substitutions that result in the following amino acid substitutions for the fetal 
NaV1.5: T206V, T207S, F209N, V210I, D211K, V215L and S234P.52,85,88 Alternative splicing of 
fetal NaV1.5 is developmentally regulated (also see Chapter II).88  
 Fetal NaV1.5 was first observed in two independent studies in a human neuroblastoma 
cell line and in a highly metastatic human breast cancer cell line.89,90 Further investigation of 
fetal NaV1.5 revealed that it is also expressed in human, rat, and mouse brain tissues.88 In 
addition, fetal NaV1.5 is strongly expressed in neonatal mouse heart but is down-regulated in 
later developmental stages.90 The exon 6A alternative splicing mechanism is also conserved in 
5 other sodium channel genes (SCN1A, SCN2A, SCN3A, SCN8A, SCN9A).88 
  It is important to consider that fetal NaV1.5 exhibits differential biophysical properties 
compared with adult NaV1.5 as demonstrated by whole-cell electrophysiological recordings of 
heterologously expressed channels. Most notably, fetal NaV1.5 exhibits a more depolarized  
conductance-voltage relationship (activation curve) compared with the adult isoform that is 
dependent on a single charged amino acid residue, a lysine (K) at position 211.52,85 This 
suggests that the fetal NaV1.5 may exert a unique effect on the electrical properties of the fetal 
heart.88 Furthermore, fetal NaV1.5 may also be important in the pathophysiology of perinatal 
forms of LQTS.  
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Figure 6: Alternative splicing of NaV1.5. 
Fetal NaV1.5 is a result of developmentally regulated alternative splicing mechanism that 
includes exon 6A in the final mRNA transcript. This mechanism results in seven amino acid 
substitutions between S3 and S4 of DI of the cardiac sodium channel compared to the 
canonical adult isoform.  
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 Therefore, we hypothesized that fetal NaV1.5 will provide a more sensitive background 
for SCN5A mutations identified in early life (fetal through infancy) and will result in 
exacerbation of cardiac sodium channel dysfunction. Four early onset LQT3 mutations were 
compared to an SCN5A mutation that is associated with a later onset of the arrhythmia (Figure 
5) in order to better understand the molecular mechanism of fetal NaV1.5. To test this 
hypothesis, we transfected tsA201 cells with the wild-type (WT) or mutant fetal NaV1.5 and WT 
or mutant adult NaV1.5, then examined the effects of each mutation by whole-cell 
electrophysiological recording. Comparisons of the biophysical properties of these alleles in 
the two splice variants as well as a comparison of the two groups (early onset vs. adult onset 
arrhythmias) are shown in Chapters II & III. The goal of these studies was to elucidate the 
biophysical properties of NaV1.5 mutations expressed in fetal NaV1.5 giving important new 
insight into arrhythmia susceptibility manifested during perinatal life. 
 We also hypothesized that fetal NaV1.5 alternative splicing alters the pharmacology of 
WT NaV1.5 and mutant NaV1.5-L409P/R558 especially in the mutant channels. Lidocaine, a 
class Ib anti-arrhythmic drug and sodium channel blocker, is a current experimental treatment 
for fetal LQTS. In addition, previous studies were preformed in our laboratory on the 
pharmacology of a splice variant of SCN1A (SCN1A-5N) which is the conserved splicing event 
exhibited for the fetal NaV1.5.90,91 The splice variant SCN1A-5N exhibited enhanced tonic block 
and use-dependent block by phenytoin and lamotrigine, across a range of stimulation 
frequencies and concentrations as well as induced shifts in steady-state inactivation and 
recovery from fast inactivation. These data suggest that the splice variant is more sensitive to 
commonly used anti-epileptic drugs. To test the hypothesis that mutant fetal NaV1.5 may 
exhibit differential biophysical effects in the presence of lidocaine compared to WT fetal 
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channels, we transfected tsA201 cells with WT fetal NaV1.5 or fetal NaV1.5-L409P/R558, then 
examined the effects of lidocaine on each condition by whole-cell electrophysiological 
recording. The studies shown in Chapter II investigated the pharmacology of WT and mutant 
(L409P/R558) fetal NaV1.5. The goal of these studies and proposed future work is to evaluate 
lidocaine as a current treatment for fetal ventricular arrhythmias.  
 Recent evidence from our laboratory has revealed that de novo calmodulin mutations 
are also associated with a severe neonatal LQTS causing recurrent cardiac arrest during 
infancy.92 One plausible contributing molecular mechanism for LQTS in these cases may be 
NaV1.5 dysfunction. We hypothesized that calmodulin mutations would result in more severe 
functional consequences when co-expressed with the fetal NaV1.5 compared to the adult 
isoform of the channel. To test this hypothesis, we transfected tsA201 cells with either fetal or 
adult NaV1.5 in combination with either the WT or mutant calmodulins (CALM1-D130G, 
CALM1-F142L, CALM2-D96V, CALM2-D134H, CALM2-D132E, CALM1-F90L). We 
ascertained the effects of each mutation by whole-cell electrophysiological recording and 
compared the biophysical properties of the two splice variants. The studies in Chapter IV will 
elucidate the molecular mechanism of calmodulin mutations on the functional effects of 
NaV1.5. These experiments provide an important insight into arrhythmia susceptibility 
associated with “calmodulinopathies” in early life.   
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CHAPTER II 
 
Developmentally Regulated SCN5A Splice Variant Potentiates Dysfunction of a Novel 
Mutation Associated With Severe Fetal Arrhythmia* 
 
INTRODUCTION 
  
 
 Congenital long-QT syndrome (LQTS) refers to a group of disorders with primary 
impairment of myocardial repolarization predisposing to life-threatening cardiac arrhythmias 
especially torsades de pointes (TdP) that are caused by genetic mutations in cardiac ion 
channels or channel modulating proteins.93 The disease is typically recognized in late 
childhood or early adolescence but extreme cases may present during infancy or in the 
perinatal period.45,47,94 Clinical signs suggestive of fetal LQTS include ventricular tachycardia, 
second degree atrioventricular (AV) block, and most commonly, sinus bradycardia but such 
findings may go undetected owing to the lack of routine electrocardiographic testing of 
fetuses.95,96 
 Evidence for Mendelian inheritance is not always apparent in cases of fetal LQTS 
because of de novo mutations or germ line mosaicism.53,54 Certain SCN5A mutations, many of 
which are de novo present with earlier onset and more severe congenital arrhythmia 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
* Modified from Murphy et al. Heart Rhythm Journal. (2012).  
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syndromes than is typical for LQTS.45,47,49,50,94,97–99 The reason for greater severity and lethality 
of certain genetic variants during early life is unknown.  
 Here we describe the clinical, electrocardiographic, and genetic diagnosis of LQTS in a 
fetus at 19 weeks gestation presenting with ventricular tachycardia and severe hydrops 
fetalis.52 To our knowledge, this is the earliest gestational age at which a diagnosis of LQTS 
has been made after being suspected on the basis of clinical presentation. A novel, de novo 
SCN5A mutation (L409P) combined with a common genetic variant (H558R) was discovered in 
the proband. The SCN5A polymorphism, H558R, is present in 20% of the Caucasian 
population and is also found in other ethnic backgrounds.66–70 The proband was homozygous 
for H558R. Therefore, we chose to investigate the molecular consequences of this mutation 
and the common genetic variant (L409P/R558) on sodium channel function.  
 Our laboratory has demonstrated prominent expression of an alternatively spliced 
NaV1.5 mRNA transcript in fetal and neonatal human heart that differs from the adult isoform 
by several residues within a voltage-sensor domain (Chapter I, Figure 6). Therefore, we 
hypothesized that mutations associated with sudden death in early life (fetal through early 
infancy) have more severe functional consequences when expressed in the context of fetal 
NaV1.5 as compared with the adult splice variant. To elucidate the functional consequences of 
the mutation, we preformed in vitro electrophysiological experiments comparing WT and 
mutant (L409P/R558) human cardiac sodium channels in the canonical channel and in the 
alternatively spliced form of NaV1.5 expressed in fetal heart. Additionally, we hypothesized that 
fetal NaV1.5-L409P/R558 may exhibit differential pharmacological effects compared to WT in 
the presence of a sodium channel blocker. Therefore, we also investigated the 
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pharmacological effects of lidocaine, a treatment for fetal arrhythmias, on WT and mutant 
L409P/R558 fetal sodium channels.  
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METHODS 
 
Testing for mosaicism 
 Parental DNA extracted from blood, saliva and buccal swabs was examined by direct 
sequence, restriction enzyme digest (EagI, MspI or NciII) and Taqman allelic discrimination 
assay.  
 
Measurement of cardiac SCN5A expression  
 De-identified, frozen, postmortem heart tissues from white-American subjects were 
obtained from the Brain and Tissue Bank of the University of Maryland under an exemption for 
human subject research granted by the Vanderbilt University institutional review board. Total 
RNA was extracted from pulverized heart muscle using TRIzol reagent (Invitrogen, Carlsbad, 
CA) followed by DNase digestion and final purification with RNeasy MinElute (Qiagen, 
Valencia, CA). RNA quality was determined by spectrophotometry and gel electrophoresis, 
and samples exhibiting degradation were not used. Reverse transcription was performed using 
3 µg RNA, 3.75 µM random hexamers (Applied Biosystems, Foster City, CA), 0.5 mM 
deoxynucleoside triphosphates (Roche, Basel, Switzerland), 1x M-MLV buffer (Promega, 
Madison, WI), 10 mM DTT, 40 units RNase inhibitor (Promega), and 200 units M-MLV reverse 
transcriptase (Promega). Reverse-transcription reactions were incubated sequentially for 5 min 
at 65°C, 2 min at 42°C, 10 min at 25°C, 50 min at 42°C, then 15 min at 70°C. Real-time 
quantitative RT-PCR using TaqMan probes specific for SCN5A exon 6 (VIC- 
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TTACGCACCTTCCGAGTC-MGB [MGB, minor groove binder]) or 6A (FAM- 
TTCGAACTTTCAGAGTCC-MGB) were used to measure relative levels of mRNA transcripts 
containing  either of these alternate exons. Amplification primers (forward: 
CCATGGAACTGGCTGGACTT; reverse: GACCATCACATCAGCCAGCTT) used in the assay 
generated a 192 bp amplicon (nucleotides 574-765 based on the open reading frame of 
Genbank:NM_198056) with a two-temperature cycling protocol (95°C for 20 s followed by 45 
cycles of 95°C, 1 s and 60°C, 30 s). Under these conditions, neither TaqMan probe exhibited 
cross-reactivity with the opposite allele. All reactions were performed in triplicate on a 7900HT 
Fast Real-Time PCR system (Applied Biosystems). Individual reactions (20 µl) contained 1x 
Fast Universal PCR Master Mix (Applied Biosystems), forward and reverse primers (3 µM), an 
allele-specific probe (10 µM), and 5 µl of cDNA (or 5 µl water for template-negative controls). 
The ability of the assay to quantitatively distinguish different proportions of the two alleles with 
high specificity was assessed using plasmid cDNA standards in the following mass ratios 
(exon 6:6A): 4:1, 2:1, 1:1, 1:2, and 1:4. The cDNA standards were diluted to a final 
concentration of 0.025 ng/µl after preliminary studies determined that this concentration 
produced cycle threshold values similar to heart tissue RNA. Assays were performed in 
triplicate and each RNA sample was assayed from 2-3 independent preparations of cDNA. 
Initial data analysis was performed using Applied Biosystems Sequence Detection System 
software (version 2.2.2). Cycle threshold (CT) values were used to generate a log2-based 
standard curve from cDNA standards and then sample CT values were used to interpolate 
expression levels for each splice isoform. Finally, ratios of mRNA transcripts containing 
SCN5A exon 6A compared with exon 6 were calculated.  
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Mutagenesis and heterologous expression of human cardiac sodium channel 
 Mutagenesis of recombinant human cardiac sodium channel (NaV1.5) was performed as 
described previously, except that a rare variant present in the original cDNA (glutamine-1027; 
Genbank accession number M77235) was reverted to the common allele (arginine-1027).47,100 
The common variant R558 was engineered in some constructs to match the genotype of the 
study subject. Wild-type (WT), R558 variant, or L409P/R558 mutant channel cDNA (0.5 µg) 
were transiently transfected into tsA201 cells using FuGene 6 (Roche Diagnostics, 
Indianapolis, IN) combined with a plasmid encoding enhanced green fluorescent protein 
(IRES2-eGFP, 0.5 µg). Initial experiments co-expressed the β1 subunit cDNA (IRES2-eGFP-
hβ1, 0.5 µg) with NaV1.5 in place of IRES-eGFP. Transiently transfected cells were incubated 
for 48 hours at 37°C prior to electrophysiological measurements. Cells exhibiting green 
fluorescence were selected for patch-clamp recordings. A fetal NaV1.5 cDNA was engineered 
by making the following amino acid substitutions encoded by the alternate exon 6 (designated 
exon 6A): T206V, T207S, F209N, V210I, D211K, V215L, S234P. 
 
In vitro electrophysiology  
 Sodium currents were recorded at room temperature using the whole-cell patch clamp 
technique as described previously.47,58 The extracellular bath solution contained the following 
(in mmol/L): 140 NaCl, 4 KCl, 1.8 CaCl2, 1 MgCl2, 10 HEPES, and 10 glucose, pH 7.35 
(adjusted with NaOH). Osmolality of the bath solution was adjusted to 300mOsm/L with 
sucrose. The intracellular pipette solution contained the following (in mmol/L): 10 NaF, 105 
CsF, 20 CsCl, 2 EGTA, 10 HEPES, 10 glucose, pH 7.35 (adjusted with CsOH). Osmolality of 
the intracellular solution was adjusted to 310mOsm/L with sucrose. Data were acquired with an 
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Axopatch 200B patch-clamp amplifier and pClamp 10.2 software. Electrode resistance ranged 
from 1.0 to 1.5 MΩ. Pipette resistance and junction potential were corrected and whole-cell 
capacitance and series resistance were 90% compensated (voltage error ≤ 2 mV). Voltage-
clamp pulse protocols assessing channel activation, steady-state inactivation, recovery from 
inactivation, and RAMP current are depicted in figure insets. TTX-sensitive persistent current 
was determined with a 200-ms depolarization to -30 mV as the average current recorded 
between 190 and 200 ms and reported as a percentage of peak current following digital 
subtraction of currents recorded in the presence and absence of 30 µmol/L tetrodotoxin (Tocris 
Biosciences, Ellisville, MO). For pulse train experiments, cells were pulsed at frequencies of 1 
and 2 Hz with 400ms pulses to -20 mV with a holding potential of -90 mV at room temperature. 
Sodium current was normalized to the level of current at the first pulse. All data were analyzed 
with pClamp 10.2 (Axon Instruments, Inc, Sunnyvale, CA) and plotted using Sigmaplot 10.0 
(SPSS, Inc, Chicago, IL) software. Results are presented as mean ± SEM. Unless otherwise 
noted, statistical comparisons were made by using an unpaired Student t test in reference to 
WT NaV1.5. Statistical significance was assumed for P < 0.05. 
 
Lidocaine pharmacology  
 Pulse train experiments were performed at room temperature on heterologous cells 
expressing WT or mutant NaV1.5 in the absence and presence of 100 µM lidocaine HCL 
(Sigma Aldrich, St. Louis, MO).  Cells were pulsed at a frequency of 2 and 5 Hz with 50 ms 
pulses to -20 mV with a holding potential of -120 mV. Recordings were performed at room 
temperature. Sodium current was normalized to the level of current at the first pulse. 
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RESULTS 
 
 
Identification of a novel SCN5A mutation in a fetus with torsades de pointes  
 A 29-year-old primiparous woman was referred for evaluation of an irregular fetal heart 
rhythm at 19-6/7 weeks gestation (by last menstrual period and an 11 week ultrasound). There 
was no family history of pregnancy loss, syncope, seizures, sudden cardiac death at any age, 
accidental death or drowning. An initial fetal echocardiogram at 20 weeks gestation disclosed 
normal cardiac anatomy with decreased ventricular function, mild tricuspid valve insufficiency 
and a very small pericardial effusion. The atrial rate was regular at 130-160 beats per minute 
(bpm) but the ventricular rate was variable. There were frequent premature ventricular 
contractions and couplets, and short (3-4 beat) runs of tachycardia (Figure 7A). During non- 
sustained tachycardia, the atrial rate was slower than the ventricular rate, leading to a 
presumptive diagnosis of ventricular tachycardia. There was no evidence of AV block. 
Maternal electrolytes were normal, and serum testing for maternal SSA/SSB antibodies, IgG to 
cytomegalovirus and Toxoplasma gondii were negative. The QTc intervals determined from 
12- lead ECG recordings were in the normal range for the patient and fetus’ father (424 ms 
and 383 ms, respectively). At 20-6/7 weeks, a fetal magnetocardiogram (fMCG) revealed 
frequent short episodes of polymorphic ventricular tachycardia consistent with TdP and a QTc 
interval of 604 msec (Figure 7B & 7C). During 2 hours of data recording, AV block was not 
observed. An ultrasound the same day showed interval accumulation of pleural fluid and 
ascites consistent with hydrops fetalis.  
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Figure 7: Fetal Doppler echocardiogram and magnetocardiogram. (A) Pulsed wave 
Doppler of the fetal aorta at 20 weeks gestation. Normal conducted beats (red arrows) are 
interrupted by frequent premature beats (PBs), and 2-3 beat runs of tachycardia with variable 
cycle length (white arrows). The flow velocity is maintained during the short runs of 
tachycardia, suggesting stroke volume is only slightly diminished. (B) Signal averaged ‘butterfly 
plot’ determined by fetal magnetocardiography during sinus rhythm at 20-6/7 weeks gestation 
illustrating T-wave alternans, a QTc interval of 604 msec, normal PR interval and a QRS 
duration that was slightly prolonged for age (0.69 msec). (C) Representative rhythm trace 
obtained by fetal magnetocardiography at 20-6/7 weeks gestation. Arrows indicate sinus beats 
interrupted by two episodes of non-sustained polymorphic ventricular (V) tachycardia (torsades 
de pointes) with varying cycle length (400 to 200 msec). (D) Pulsed wave Doppler of the 
middle cerebral artery at 22 weeks gestation illustrating fetal arrhythmia. At this time, the fetus 
was severely hydropic with very poor systolic function (not shown). The tracing shows the 
onset of a sustained period (> 3500 msec) of ventricular tachycardia (white arrows), initiating 
by a premature beat (PB). During the tachycardia, there is decreased stroke volume as 
evidenced by the extremely low velocity Doppler signals. The tachycardia cycle length was 480 
to 210 ms. 
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Treatment of the fetal arrhythmia was discussed with the family, however, because of the dire 
clinical status, the parents elected not to pursue treatment. 
 Echocardiography at 22 weeks gestation revealed severe cardiac dysfunction, more 
frequent and more prolonged episodes of ventricular tachycardia (Figure 7D), and worsening 
hydrops fetalis. Although tachycardia cycle length was similar to that observed 2 weeks prior 
(Figure 7A), the velocity of the Doppler signals were extremely low, suggesting that the stroke 
volume was greatly decreased during tachycardia episodes. At this time, tachycardia episodes 
had a longer duration, and the intervals between tachycardia episodes were shorter (not 
shown) implicating increased tachycardia burden as a factor for the progression of cardiac 
dysfunction.  
 Based on the extent of clinical deterioration, the pregnancy was terminated at the request 
of the family. Postmortem genetic testing (Familion, New Haven, CT, USA) of the fetus 
identified a novel heterozygous SCN5A transition mutation (T1226C) predicting a missense 
change in codon 409 from leucine to proline (designated SCN5A-L409P). The fetal proband 
was also homozygous for a common nonsynonymous variant, R558. However, extensive 
analysis of parental DNA identified no evidence of germline mosaicism suggesting that 
SCN5A-L409P occurred on a de novo basis in the fetus. 
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Functional Consequences of SCN5A-L409P  
 We determined the functional consequences of SCN5A-L409P by in vitro 
electrophysiological recording of heterologously expressed recombinant human cardiac 
sodium channels (NaV1.5). To recapitulate the genotype of the fetus, we engineered the L409P 
mutation along with the R558 variant (combination allele designated as L409P/R558). 
Expression of mutant channels in tsA201 cells generated voltage-dependent sodium currents 
that exhibited several differences compared to WT NaV1.5 including a trend toward reduced 
peak current density (Figure 8A & B), significant depolarized shifts in the voltage-dependence 
of steady-state inactivation and conductance-voltage relationships (Figure 8C; Table 2), and 
markedly accelerated recovery from inactivation (Figure 8D). Additionally, as compared to WT 
channels, L409P/R558 exhibited a 7-fold greater level of persistent sodium current measured 
as a percentage of peak current (1.4 ± 0.2%, Figure 9A; Table 1). Increased persistent current 
is the most frequently observed functional disturbance exhibited by SCN5A mutations 
associated with LQTS,101 and can also explain abnormal inward current evoked by a slow 
depolarizing voltage ramp (Figure 9B & C). The overall findings indicate that L409P/R558 
causes dysfunction of cardiac sodium channels consistent with cardiac arrhythmia 
predisposition. However, these findings do not provide an explanation for the severe 
intrauterine presentation of ventricular arrhythmia.  
 We also repeated these experiments with co-expression of the auxiliary β1 subunit with 
NaV1.5 (Figure 10). In the presence of β1, the current density of both WT and mutant channels 
increased. However this was not significant compared to channels in the absence of β1 
subunits. Overall, L409P/R558 exhibited similar effects in the presence and absence of β1 
compared to respective WT channels.  
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Figure 8: Biophysical properties of WT and mutant sodium channels. 
(A) Representative whole-cell current recordings from cells expressing either WT (adult 
NaV1.5- H558) or mutant (adult NaV1.5-L409P/R558) channels (voltage protocol shown as 
inset). (B) Current-voltage relationships for WT (n = 10) and mutant (n = 10) channels. Current 
was normalized to cell capacitance to give a measure of current density. (C) Superimposed 
curves representing the voltage dependence of steady-state inactivation (left y-axis) and 
conductance- voltage (right y-axis) relationships for WT and mutant channels. Lines represent 
average fits of the data with Boltzmann functions. (D) Time course of recovery from 
inactivation recorded using the illustrated voltage protocol. Biophysical fit parameters for all 
experiments are provided in Table 2. 
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Figure 9: SCN5A-L409P/R558 exhibits increased persistent current.  
(A) Representative tetrodotoxin (TTX)-sensitive currents were normalized to the peak current 
measured at -30mV during a 200 ms depolarization to illustrate persistent current. The inset 
represents the same data plotted on an expanded vertical scale. Summary data are provided 
in Table 1. (B) WT and mutant currents elicited by voltage ramps defined by the inset. (C) 
Amount of charge moved between -70 and -30mV normalized to peak current and quantified. 
Charge movement was significantly (p < 0.02) greater for mutant (10.2 ± 4.3 pC/nA, n = 9) 
than for WT (5.1 ± 4.0 pC/nA, n = 9) channels. 
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Figure 10: β1 subunit does not significantly affect L409P/R558 channel function.  
(A) Current density-voltage relationships recorded from cells expressing either WT NaV1.5 (n = 
10), NaV1.5-L409P/R558 (n = 10), WT NaV1.5 + β1 (n = 9), or NaV1.5-L409P/R558 + β1 (n = 4) 
channels (voltage protocol in the inset). (B) Conductance-voltage relationships for WT and 
mutant channels in the presence of absence of β1 subunits. (C) Steady-state voltage 
dependence of inactivation for WT and mutant channels (n = 4-10). In (B) and (C) lines 
represent average fits of the data with Boltzmann functions. (D) Time course of recovery from 
inactivation recorded using the illustrated voltage protocol.  
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Recovery from inactivation of WT channels co-expressing β1 was significantly faster than WT 
channels without β1. However, this was not consistent with previous studies investigating β1 
effects on channel function. Previous studies in CHO cells over-expressing β1 have shown that 
β1 has no effect on recovery from inactivation, shifts the voltage-dependence of activation and 
inactivation to more hyperpolarized potentials, and significantly increases current density 
compared to NaV1.5 without β1.102–104 Therefore we concluded that β1 does not have 
additional effects on the mutant NaV1.5 channels despite differences in WT channel function in 
the presence of β1.  
 
Developmental regulation of SCN5A exon 6 splicing  
 We hypothesized that the severity of LQTS presentation in this fetus was due to more 
severe functional consequences conferred by the mutant genotype in the background of a 
fetal-expressed alternatively spliced SCN5A transcript. We focused on the developmentally 
timed alternative splicing of exon 6 that generates two splice isoforms differing by seven amino 
acid residues within a voltage-sensing domain (D3/S3-S4) originally described in 
neuroblastoma cells.105 We determined the relative levels of SCN5A mRNA transcripts 
containing the canonical exon 6 or the alternative exon 6A in human heart samples 
representing various developmental stages including the fetal period (28-33 weeks gestation), 
infancy (2-6 months of age) and adulthood (> 18 years of age). 
 In fetal human heart, we observed ~1.5-fold greater levels of SCN5A mRNA transcript 
containing exon 6A, encoding what we designated as fetal NaV1.5, as compared with 
transcripts containing the canonical exon 6, encoding the adult splice variant of NaV1.5 (Figure 
11). In hearts from infants, the relative abundance of adult and fetal NaV1.5 mRNA was  
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Figure 11: Developmental timing of SCN5A exon alternative splicing. 
Expression ratio (exon 6A / exon 6) of SCN5A mRNA transcripts expressed in human fetal (n = 
4), infant (n = 4) and adult (n = 24) hearts determined by quantitative real-time RT-PCR. 
Differences among groups was significant at p < 0.0001 (one-way ANOVA with Tukey test). 
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approximately equal, while in adult heart there was a 7.5-fold higher level of adult NaV1.5 
mRNA as compared to the fetal splice variant. The fetal (exon 6A) to adult (exon 6) NaV1.5 
expression ratio in adult heart was significantly different from both infant and fetal heart (p < 
0.0001) whereas differences between fetal and infant heart expression ratios were not 
significant (p = 0.06). We conclude that SCN5A exhibits a developmental switch in exon 6/6A 
alternative splicing in human heart during early postnatal life. 
 
Functional properties of WT and mutant fetal NaV1.5 
 To test whether the functional consequences of L409P/R558 are different in fetal 
NaV1.5, we engineered a recombinant human fetal NaV1.5 cDNA and compared its 
electrophysiological properties to adult NaV1.5. We demonstrated that fetal NaV1.5 exhibits a 
significantly more positive midpoint (+9 mV shift in V1/2) in the conductance-voltage relationship 
as compared with the adult splice variant, but no significant differences in peak current density, 
voltage- dependence of steady-state inactivation curve or recovery from inactivation (Figure 
12; Table 2). These data demonstrate intrinsic differences in biophysical properties between 
human fetal and adult NaV1.5 splice isoforms. 
 We investigated the consequences of the common SCN5A variant R558 on the 
functional properties of fetal NaV1.5 and compared these to the effect of the variant on the 
adult splice isoform. Whereas, R558 has minimal functional impact on adult NaV1.5 (Table 2), 
the expression of this variant in fetal NaV1.5 demonstrates substantial effects including lower 
whole cell current density and a large persistent sodium current (Figure 13; Table 1). These 
findings demonstrate a considerable functional defect for the non-mutant allele, R558. 
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Figure 12: Comparison of biophysical properties for adult and fetal NaV1.5 channels.  
(A) Representative whole-cell current recordings from cells expressing either adult NaV1.5 or 
fetal NaV1.5 obtained using the illustrated voltage-clamp protocol. Both channel isoforms 
included the common allele at position 558 (H558). (B). Current-voltage relationships for adult 
NaV1.5 and fetal NaV1.5. Current was normalized to cell capacitance to give a measure of 
current density. (C) Conductance-voltage relationships for adult NaV1.5 and fetal NaV1.5. (D) 
Steady-state voltage dependence of inactivation for adult NaV1.5 and fetal NaV1.5. In (C) and 
(D) lines represent average fits of the data with Boltzmann functions. (E) Time course of 
recovery from inactivation recorded using the illustrated voltage protocol. Biophysical fit 
parameters for all experiments are provided in Table 2. Data were collected from 10-11 cells. 
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Figure 13: Functional consequences of R558 variant on fetal-NaV1.5.  
(A) Current density-voltage relationships recorded from cells expressing either WT (labeled 
fetal-NaV1.5-H558; n = 11) or variant (fetal NaV1.5-R558; n = 14) channels (voltage protocol 
same as in Figure 8A). (B) Conductance-voltage relationships for WT and variant channels. 
(C) Steady-state voltage dependence of inactivation for WT (n = 10) and variant channels (n = 
10). In (B) and (C) lines represent average fits of the data with Boltzmann functions. (D) 
Averaged TTX-sensitive persistent currents measured at -30mV during a 200 ms 
depolarization and normalized to peak current (n = 7). The inset represents the same data 
plotted on an expanded vertical scale. Biophysical fit parameters for all experiments are 
provided in Table 2, and magnitude of persistent current is provided in Table 1. 
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 Finally, we determined the functional consequences of L409P/R558 in fetal NaV1.5. 
Compared with biophysical properties of this mutation in the adult isoform, L409P/R558 in fetal 
NaV1.5 exhibited greater depolarizing shifts in steady-state inactivation and in conductance-
voltage relationships (Figure 14; Table 2), and greater persistent current (Figure 14; Table 1). 
Superimposed, normalized current traces (Figure 14D) and quantitative analysis also illustrate 
slower activation rise time and slower kinetics of inactivation for fetal NaV1.5-L409P/R558 as 
compared with WT fetal NaV1.5, functional defects that were not as prominent in the adult 
splice isoform (Figure 15). Collectively, these observations indicate that both SCN5A alleles 
carried by this fetus, one with R558 alone and the other with L409P/R558, cause much more 
profound sodium channel dysfunction in the background of fetal NaV1.5 splice isoform 
providing a plausible explanation for severe presentation of intrauterine LQTS. 
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Figure 14: Expression in fetal NaV1.5 potentiates effect of SCN5A-L409P/R558.  
(A) Current density-voltage relationships comparing WT and mutant channels expressed in 
either adult or fetal NaV1.5 channels (voltage protocol same as in Figure 8A; n = 10 for all 
groups). (B) Conductance-voltage relationships for WT and mutant channels. (C) Steady-state 
voltage dependence of inactivation for WT and mutant channels (n = 10-12). In (B) and (C) 
lines represent average fits of the data with Boltzmann functions. (D) Representative TTX-
sensitive persistent currents measured at -30mV during a 200 ms depolarization and 
normalized to peak current. Biophysical fit parameters for all experiments are provided in Table 
2 and magnitude of persistent current is provided in Table 1. 
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Table 1: Persistent TTX- sensitive sodium current measured at -30mV.  
 
Persistent Current  
(% of peak INa) 
Current Density (pA/pF) n 
Nav1.5-H558 0.2 + 0.4 0.4 ± 0.1 8 
Nav1.5-R558 0.4 + 0.2 0.4 ± 0.2 3 
Nav1.5- L409P/R558 1.4 + 0.2 b 2.5 ± 0.9 a 7 
Fetal Nav1.5-H558 0.7 + 0.3 a 1.3 ± 0.9 4 
Fetal Nav1.5-R558  3.7 + 0.9 bc 3.5 ± 1.2 a 7 
Fetal Nav1.5-L409P/R558 11.1 + 1.5 bc 4.4 ± 1.2 a 10 
a P < 0.05 compared to  Adult Nav1.5-H558      b P < 0.005 compared to Adult Nav1.5-H558       
c P  < 0.05 compared to Fetal Nav1.5 -H558     d P < 0.005 compared to Fetal Nav1.5-H558      
ANOVA and Dunn’s Test  
Table 2: Biophysical parameters for WT, variant, and mutant NaV1.5 channels expressed 
in either adult or fetal splice isoform. 
Voltage-Dependence of 
Activation Steady-State Availability 
Recovery From 
Inactivation   
V 1/2  (mV) k (mV) n V 1/2  (mV) k (mV) n τ (msec) n 
Nav1.5-H558 -50.9 + 2.3 5.7 + 0.7 10 -102.0 + 2.0 -9.0 + 0.3 10 6.0 ± 0.4 10 
Nav1.5-R558 -45.8 + 2.9 6.5 + 0.8 5 -102.8 + 1.8 -9.2 + 0.8 5 13.4 ± 2.0 a 4 
Nav1.5- 
L409P/R558 -39.7 + 2.9 
a 8.9 + 0.3 b 10 -93.9 + 1.6 b -7.6 + 0.2 b 11 1.4 ± 0.1 a 8 
Fetal Nav1.5-
H558 -38.2 + 1.5 
b 6.9 + 0.4 11 -96.9 + 1.8 -8.9 +0.3 10 6.8 ± 0.3 7 
Fetal Nav1.5-
R558 -32.9 + 2.1 
b 10.0 + 0.5 bc 14 -98.5 + 2.7 -10.4 + 0.3 ac 10 8.8 ± 3.0 6 
Fetal Nav1.5-
L409P/R558 -20.8 + 1.5 
bce 11.0 + 0.5 bce 10 -85.3 + 1.1 bce -9.0 + 0.5 d 12 1.2 ± 0.1 cd 4 
a P < 0.05 compared to  Adult Nav1.5-H558            b P < 0.005 compared to Adult Nav1.5-H558       
c P  < 0.05 compared to Fetal Nav1.5 -H558     d P < 0.05 compared to Fetal Nav1.5-R558          
e P < 0.005 compared to Fetal Nav1.5-R558           ANOVA and Dunn’s Test  
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Figure 15: Activation and inactivation kinetics for WT and mutant channels.  
(A) Time to peak current activation is compared for WT (fetal NaV1.5-H558; n = 7) and mutant 
(fetal NaV1.5-L409P/R558; n = 6) channels expressed in the fetal splice isoform (exon 6A). (B) 
Time constants of inactivation for WT (n = 7) and mutant (n = 9) fetal NaV1.5 channels. Values 
were derived from single exponential fits to the decay phase of the current. (C) Time to peak 
current activation is compared for WT (NaV1.5-H558; n = 8) and mutant (NaV1.5-L409P/R558; 
n = 7) channels expressed in the adult splice isoform (exon 6). (D) Time constants of 
inactivation for WT (n = 10) and mutant (n = 10) adult NaV1.5 splice variant. Values were 
derived from single exponential fits to the decay phase of the current. In each panel, asterisks 
mark values statistically different at the p < 0.05 level (Student t-test) for a given voltage. 
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Ultra-fast recovery from inactivation and repeated stimulation of mutant adult and fetal NaV1.5 
 We initially observed that L409P/R558 expressed in both the canonical adult and fetal 
NaV1.5 backgrounds elicited an ultra-fast recovery from inactivation at -120 mV. A faster 
recovery from inactivation compared to WT channels is consistent with a destabilization of 
inactivation. Therefore we investigated whether L409P/R558 would also exhibit ultra-fast 
recovery when channels were inactivated at more extreme voltages of -140 or -90 mV using a 
similar 50ms recovery protocol as shown in the Figure 12E inset. NaV1.5-L409P/R558 
channels exhibited an ultra-fast recovery from inactivation at -90 mV (17.4 ± 3.4 ms) compared 
to WT NaV1.5 (68.7 ± 3.2 ms) but not at -140 mV (Figure 16A). Fetal NaV1.5-L409P/R558 
channels exhibited a significantly faster recovery from inactivation with smaller time constants 
at -140 mV (1.3 ± 0.2 ms) and -90 mV (9.0 ± 0.6 ms) compared to WT fetal NaV1.5 (-140 mV: 
3.3 ± 0.4 ms, -90 mV: 49.7 ± 5.9 ms) (Figure 16B). These results demonstrate that 
L409P/R558 channels exhibit an ultra-rapid recovery mechanism compared to WT channels.   
 We also investigated whether repeated stimulation of mutant sodium channels would 
result in attenuated or enhanced loss of channel availability compared to WT channels. WT 
and mutant sodium channels were pulsed at a frequency of 1 or 2 Hz and currents were 
normalized to the first pulse. It is important to note that the frequency of 2 Hz is similar to the 
fetal heart rate (~120 bpm) while a frequency of 1 Hz is similar to an adult heart rate (~60 
bpm).106,107 NaV1.5-L409P/R558 and fetal NaV1.5-L409P/R558 both exhibited a significantly 
attenuated loss of channel availability at both frequencies of 1 and 2 Hz (Figure 17).  
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Figure 16: L409P/R558 channels exhibit ultra-fast recovery from inactivation.  
(A) Recovery time constants at -140, -120, and -90 mV of WT NaV1.5 (n = 5) and NaV1.5-
L409P/R558 channels (n = 5). (B) Recovery time constants of WT fetal NaV1.5 (n = 5) and fetal 
NaV1.5-L409P/R558 channels (n = 5). Recovery time constants are shown on a common log 
scale. See Table 2 for recovery time constant values at -120 mV. Also see Chapter III, Table 5 
for statistical comparisons. Statistical significance was assumed for P < 0.05. 
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Figure 17: L409P/R558 channels have attenuated loss of channel availability upon 
repeated stimulation at frequencies of 1 and 2 Hz.  
(A) Normalized current of WT NaV1.5 (n = 6) and NaV1.5-L409P/R558 (n = 5) during 1 Hz 
pulse trains. (B) Normalized current of WT fetal NaV1.5 (n = 5) and fetal NaV1.5-L409P/R558 (n 
= 5) during 1 Hz pulse trains. (C) Normalized current of WT NaV1.5 (n = 6) and NaV1.5-
L409P/R558 (n = 5) during 1 Hz pulse trains. (D) Normalized current of WT fetal NaV1.5 (n = 5) 
and fetal NaV1.5-L409P/R558 (n = 5) during 2 Hz pulse trains. All data points shown are at 
every 5 pulses. Pulses were 50 ms long with a holding potential of -90 mV.  
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This suggests that mutant L409P/R558 channels exhibit impaired inactivation in response to 
repeat stimulation compared to WT. This observation is consistent with previous findings that 
L409P/R558 channels exhibit an ultra-fast recovery from inactivation and altered inactivation 
kinetics.  
 
Lidocaine pharmacology of WT fetal NaV1.5 and fetal NaV1.5-L409P/R558 channels 
 Lidocaine is a sodium channel blocker often administered IV to pregnant women whose 
fetuses exhibit ventricular rhythm disturbances including those with suspected fetal LQTS. The 
efficacy of this treatment strategy is variable and may depend on the genotype of the fetus. 
Other factors such as developmentally regulated SCN5A alternative splicing may also be 
critical. However, the effects of lidocaine on the fetal isoform of NaV1.5 are unknown. We 
hypothesized that certain SCN5A mutations such as L409P/R558 associated with severe 
perinatal LQTS will exhibit variable responses to lidocaine when expressed in either fetal or 
adult NaV1.5 channel isoforms.  
 We performed pulse train experiments in heterologous cells expressing WT or 
L409P/R558 fetal sodium channels in the absence and presence of 100 µM lidocaine to 
determine if the fetal NaV1.5-L409P/R558 exhibited altered pharmacology compared to WT 
channels. In the presence of lidocaine, WT fetal channels exhibited use-dependent loss of 
channel availability compared WT channels in the absence of lidocaine at 2 and 5 Hz  (Figure 
18). However, fetal NaV1.5-L409P/R558 channels in the presence of lidocaine were resistant 
to lidocaine block at 2 and 5 Hz (Figure 18A & B).  
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Figure 18: Fetal NaV1.5-L409P/R558 is resistant to lidocaine upon repeated stimulation.  
(A) Normalized current of WT fetal NaV1.5 (n = 1) and fetal NaV1.5-L409P/R558 (n = 2) in the 
absence of lidocaine or WT fetal NaV1.5 (n = 1), fetal NaV1.5-L409P/R558 in the presence of 
lidocaine (n = 2) during 2 Hz pulse trains. (B) Normalized current of WT fetal NaV1.5 (n = 1) 
and fetal NaV1.5-L409P/R558 (n = 2) in the absence of lidocaine, or WT fetal NaV1.5 (n = 1), 
fetal NaV1.5-L409P/R558 (n = 2) in the presence of lidocaine during 5 Hz pulse trains. These 
experiments were not performed with the adult NaV1.5. Pulses were 50 ms long with a holding 
potential of -120 mV (see Methods). 
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This suggests that some SCN5A mutations such as L409P/R558 that are associated with fetal 
LQTS may be resistant to lidocaine treatment.  
 
Discussion 
 The novel SCN5A mutation we identified in this study encodes a dysfunctional cardiac 
sodium channel, but the degree of channel dysfunction determined in the context of the 
canonical adult NaV1.5 splice product did not explain the unusual severity and early onset of 
fetal arrhythmia. We considered that using the adult NaV1.5 splice isoform to evaluate the 
functional consequences of a mutation associated with an intrauterine arrhythmia might be 
misleading if another molecular form of the channel was predominant in fetal heart. SCN5A 
undergoes alternative mRNA splicing to generate multiple isoforms of the protein.88  
 Although many described splicing events have uncertain physiological significance, at 
least one major alternative splicing event could have implications for understanding severe 
fetal LQTS. Specifically, a developmentally regulated SCN5A splicing event involving selection 
between two alternative forms of exon 6 generates NaV1.5 isoforms that differ at several amino 
acid residues within a voltage-sensor domain (D1/S3-S4).88,105 This alternative NaV1.5 splice 
variant is strongly expressed in neonatal mouse heart but is down-regulated later in 
development.90 Evidence for developmentally regulated expression in humans was not 
previously demonstrated. Here we show prominent expression of alternatively spliced NaV1.5 
mRNA incorporating exon 6A in fetal and infant heart. Previous studies have referred to this 
product of alternative splicing as a ‘neonatal’ SCN5A,85,88 but given the high level of expression 
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we observed in fetal human heart (Figure 11), we suggest that fetal NaV1.5 is a more 
appropriate designation. 
 Hence, we investigated the functional consequences of the mutation in the fetal NaV1.5 
splice isoform. These experiments indicated that the common variant (R558) and the 
compound mutant genotype (L409P/R558), the two alleles carried by the proband, each 
conferred much greater functional defects on fetal NaV1.5 than on adult NaV1.5. In particular, 
the proportion of persistent current was substantial for channels with L409P/R558 (11% of 
peak current) as well as with the R558 common variant alone (3.7% of peak current, Table 1), 
and was also abnormal for mutant adult NaV1.5. Therefore, this fetus expressed mostly 
dysfunctional SCN5A alleles at the time of the presenting arrhythmia syndrome. However we 
cannot fully explain why the common variant alone does not result in a higher prevalence of 
fetal LQTS or SIDS.  
 Previous studies investigating the effects of R558 on sodium channel function have 
shown that the common variant may modulate the biophysical defects of a rare variant 
associated with SIDS such as P2006A.108 It has also been shown that small peptides, 
spanning the H558R polymorphism, are sufficient to restore trafficking defects of Brugada 
syndrome-associated SCN5A mutations.109 However, another study investigating the effects of 
R558 discovered that the variant expressed in combination with a mutation associated with 
LQTS, SCN5A-A572D, evokes an increase in persistent sodium current compared with 
SCN5A-A572D alone.71 One possibility is that the position of the mutation (e.g. domain I) in 
combination with the R558 may be an important factor in determining whether the common 
variant will result in a pathogenic effect on NaV1.5. Additionally, these studies highlight the 
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importance of investigating the effects of R558 on other SCN5A mutations associated with 
severe cardiac arrhythmias that occur during early life.   
 In addition to our previous findings, we also demonstrated that L409P/R558 channels 
exhibited an ultra-fast recovery from inactivation at -140, -120, and -90 mV. Fetal NaV1.5-
L409P/R558 exhibited an even faster recovery than L409P/R558 in the adult background 
suggesting a more severe destabilization of the inactivated state. Furthermore, L409P/R558 
channels exhibited an attenuated loss of channel availability suggesting mutant NaV1.5 
channels may not fully inactivate during periods of frequent stimulation. Sodium channels with 
an ultra-rapid recovery mechanism may prime the cardiomyocyte for re-activation during 
ventricular repolarization. Therefore, recovery from inactivation may be an important 
biophysical property in the fetal heart under pathophysiological conditions such as re-entrant 
arrhythmias. However, further investigation of the molecular mechanism of mutant fetal NaV1.5 
in native cardiomyocytes or induced pluripotent cardiomyocytes (iPS-CMs) is required to 
determine if ultra-fast recovery from inactivation is pathological.  
 The profound defects observed for mutant fetal NaV1.5 channels explains both the 
malignant character of the arrhythmia syndrome and the early onset of this condition in utero. 
We further speculate that impaired ventricular contractility was also the result of severe sodium 
channel dysfunction and related to either tachycardia as suggested by fetal Doppler studies 
(Figure 7) or disturbances in intracellular ionic homeostasis proposed for familial dilated 
cardiomyopathy associated with SCN5A variants.79 
 Another interesting finding of these studies was that mutant fetal NaV1.5 channels are 
resistant to lidocaine treatment compared to WT when stimulated at 2 Hz and 5 Hz. Although 
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the sample size is small, the results are profound and suggest that some SCN5A mutations 
may be resistant to the current method of treatment for fetal LQTS. Further investigation is 
required to determine if the fetal NaV1.5 exhibits differential pharmacological properties 
compared to adult channels and if other SCN5A mutations associated with fetal LQTS are also 
resistant to lidocaine. Specifically, dose-response analyses would provide valuable insight on 
the pharmacology of WT and mutant fetal NaV1.5.  
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CONCLUSIONS 
 
 In summary, we present a case of fetal LQTS identified early in mid-gestation due to a 
novel, de novo SCN5A mutation. Fetal LQTS may be an under-recognized cause of early fetal 
hydrops and unexplained fetal loss, and should be considered in the differential diagnosis of 
the fetus with rapidly progressive heart failure and complex arrhythmia even if family history is 
negative. The unusual severity and early onset of arrhythmia in this case were explained by 
profound dysfunction of the mutant sodium channel carried by the fetus that was revealed only 
by considering the correct molecular context, a fetal-expressed alternatively spliced SCN5A 
transcript. Our findings demonstrate an important contribution of developmentally regulated 
alternative SCN5A splicing to the genetic risk for prenatal life-threatening cardiac arrhythmias. 
In addition, we show that mutant L409P/R558 fetal sodium channels exhibit resistance to 
lidocaine treatment, the current therapy for fetal LQTS.  
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CHAPTER III 
 
Dysfunction of a Fetal-Expressed Sodium Channel Splice Isoform is a Distinguishing 
Factor for Early Onset Type-3 Long QT-Syndrome  
 
INTRODUCTION 
 
 Mutations in the gene SCN5A encoding the cardiac voltage-gated sodium channel 
(NaV1.5) can result in severe life-threatening cardiac arrhythmias such as the long QT 
syndrome (LQTS). Severe arrhythmias such as LQTS typically present in childhood or early 
adulthood but in some extreme cases may present during the perinatal period (fetal –
infancy).45–47 Although many SCN5A mutations associated with SIDS,45,46,58 neonatal 
LQTS,48,49,110 and fetal arrhythmias52,53,111,54,112 have been investigated, the molecular basis for 
arrhythmia susceptibility in early developmental stages remains unclear.   
 The major biophysical defect of NaV1.5 that contributes to type-3 LQTS (LQT3) is 
persistent sodium current that is typically due to impaired inactivation of the channels.38 
Persistent sodium current leads to a delayed ventricular repolarization and torsades de 
pointes.44 We previously reported that developmentally regulated alternative splicing of SCN5A 
contributes to the genetic risk for prenatal life-threatening cardiac arrhythmias. We have 
demonstrated that a SCN5A mutation (L409P) associated with fetal LQTS exhibits more 
severe functional consequences when expressed in the context of a fetal-expressed 
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alternative splice variant of NaV1.5.52 Specifically, we have shown that L409P exhibited a 
greater persistent sodium current, impaired inactivation, and ultra-fast recovery kinetics in fetal 
NaV1.5 compared to wild-type (WT) channels (Chapter II).113  
 Therefore, we hypothesized that other SCN5A mutations associated with perinatal forms 
of LQTS would also exhibit more severe functional consequences such as a greater persistent 
sodium current when expressed in fetal NaV1.5. Here we demonstrate that one of three early-
onset LQT3 mutations studied, A1330D, exhibits more severe functional consequences when 
expressed in fetal NaV1.5 such as a greater persistent sodium current, a greater late current 
density, ultra-rapid recovery from inactivation, and shifts in the voltage-dependence of 
inactivation compared to WT channels. We also demonstrate that two other early-onset LQT3 
mutations, F1473C and R1623Q, exhibit similar functional effects when expressed in the fetal 
splice variant as in the adult isoform of NaV1.5.  
 Additionally, we considered the possibility that later onset (childhood-adulthood) LQT3 
mutations such as delKPQ may exhibit ‘protective’ or masked effects when expressed in the 
fetal splice variant. Here we show that delKPQ exhibits a loss of function when expressed in 
fetal NaV1.5 with a dramatic reduction in current density and late current density compared to 
the mutation expressed in the adult background.  Our findings implicate dysfunction of a fetal-
expressed sodium channel splice isoform as a distinguishing factor for the early onset of LQT3 
compared to later onset arrhythmias. In clinical settings, these results may have relevance to 
sudden cardiac death in the earliest stages of life. 
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METHODS 
 
 
Mutagenesis and heterologous expression of human cardiac sodium channel 
 Plasmids encoding recombinant human cardiac sodium channel isoforms (NaV1.5) were 
described previously.52 Site directed mutagenesis was performed using the QuikChange 
system (Stratagene) and primer sequences are available upon request. Wild-type (WT) or 
mutant channel cDNAs (0.5 µg) were transiently transfected into tsA201 cells using FuGene 
HD (Roche Diagnostics, Indianapolis, IN) combined with a separate plasmid encoding 
enhanced green fluorescent protein (pIRES2-EGFP, 0.5 µg). Transiently transfected cells were 
incubated for 48 hours at 37°C prior to electrophysiological measurements. Cells exhibiting 
green fluorescence were selected for patch-clamp recordings.  
 
In vitro electrophysiology  
 Sodium currents were recorded at room temperature using the whole-cell patch clamp 
technique as described previously.47,58 The extracellular bath solution contained the following 
(in mM): 140 NaCl, 4 KCl, 1.8 CaCl2, 1 MgCl2, 10 HEPES, and 10 glucose, pH 7.35 (adjusted 
with NaOH). The intracellular pipette solution contained the following (in mM): 10 NaF, 105 
CsF, 20 CsCl, 2 EGTA, 10 HEPES, 10 glucose, pH 7.35 (adjusted with CsOH). Data were 
acquired with an Axopatch 200B patch-clamp amplifier and pClamp 10.2 software (Molecular 
Devices, Inc., Sunnyvale, CA). Electrode resistance ranged from 1.0 to 1.5 MΩ. Pipette 
resistance and junction potential were corrected and whole-cell capacitance and series 
resistance were 90% compensated (voltage error ≤ 2 mV). Cells with <500pA of current were 
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not included in the data analysis. Voltage-clamp pulse protocols assessing channel activation, 
steady-state inactivation, and recovery from inactivation are depicted in figure insets. TTX-
sensitive persistent current was determined with a 200-ms depolarization to −30 mV as the 
average current recorded between 190 and 200 ms and reported as a percentage of peak 
current following digital subtraction of currents recorded in the presence and absence of 30 µM 
tetrodotoxin (Tocris Biosciences, Ellisville, MO). Time constants for recovery from inactivation 
were determined from single exponential fits. Unless otherwise noted, all fit amplitudes (A) 
were equal to 1.0 ± 0.1. For pulse train experiments, cells were pulsed at frequencies of 1 or 2 
Hz with 400 ms pulses to −20 mV from a holding potential of −90 mV at room temperature. 
Sodium currents were normalized to the level of current at the first pulse. All data were 
analyzed with pClamp 10.2 and plotted using SigmaPlot 10.0 (SPSS, Inc, Chicago, IL) 
software. Results are presented as mean ± SEM. Unless otherwise noted, statistical 
comparisons were made by using one-way ANOVA with Bonferroni correction. Statistical 
significance was assumed for p < 0.05. 
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RESULTS 
 
 We previously demonstrated that a novel SCN5A mutation (L409P) associated with an 
intrauterine presentation of LQTS exhibited a greater degree of dysfunction when expressed in 
a fetal splice isoform of NaV1.5 (Chapter II). We concluded from these observations that the 
pathogenesis of certain mutations may be potentiated in the fetal NaV1.5 channel. Here we 
compared the functional effects of three additional SCN5A mutations associated with severe 
and early-onset LQTS with that of a mutation associated with typical onset LQTS (delKPQ). 
Additionally, we investigated whether channel dysfunction was potentiated in fetal NaV1.5 as 
compared with the canonical splice isoform to determine if this was a common mechanism 
explaining the more severe and early onset nature of LQTS associated with certain SCN5A 
mutations. All mutant channels studied generated sodium currents in transiently transfected 
tsA201 cells with some notable differences between canonical and fetal NaV1.5 (Figure 19). 
 
Functional consequences of early onset LQT3 mutation A1330D in fetal NaV1.5 
 Mutation SCN5A-A1330D was discovered in an Italian boy with early-onset LQTS. The 
proband, a Caucasian male, was delivered by Caesarean section at 33 weeks’ gestation 
because of oligohydramnios. Birth weight was 2.3 kg and APGAR score was 9. On the second 
day of life, he exhibited bradycardia followed by an episode of ventricular fibrillation and he 
was successfully resuscitated (chest thump, defibrillation). Electrocardiogram revealed a 
prolonged QTc (500 msec) and 2:1 atrioventricular block. Echocardiography demonstrated 
normal cardiac anatomy and function. Despite treatment with lidocaine, MgSO4, propranolol  
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Figure 19: Representative traces of WT and mutant sodium currents. 
The left side shows WT and mutant adult NaV1.5 representative traces. The right side shows 
WT and mutant fetal NaV1.5 representative traces.  
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and mexiletine, the subject continued to have frequent episodes of ventricular tachycardia, 
including torsades de pointes and ventricular fibrillation prompting repeated external 
defibrillations. He died at age 70 days following a final episode of cardiac arrest. Genetic 
testing revealed a novel SCN5A mutation (A1330D) in the proband but not in the parents or 
two siblings consistent with a de novo mutation. This mutation affects the same residue as 
another de novo mutation (A1330P) associated with sudden cardiac death at age 9 weeks.45  
 Mutation SCN5A-A1330D has previously been characterized expressed in the canonical 
adult isoform of NaV1.5 and has been shown to evoke a significant increase in persistent 
sodium current compared to WT channels that is typical of LQT3 mutations.62 We determined 
the functional consequences of A1330D expressed in the fetal splice isoform of NaV1.5 by in 
vitro electrophysiological recording of heterologously expressed recombinant human cardiac 
sodium channels. We have confirmed that adult NaV1.5-A1330D evokes a 4.5-fold greater 
level of persistent sodium current measured as a percent of peak current (0.9 ± 0.1%) and a 
8.2-fold greater late current density (4.9 ± 0.8 pA/pF) compared to WT NaV1.5. By contrast, 
when A1330D is expressed in the fetal splice variant, fetal NaV1.5-A1330D evoked a 5.7-fold 
greater persistent sodium current (1.7 ± 0.2%) and a 14.5-fold greater late current density (5.8 
± 1.2 pA/pF) vs WT fetal NaV1.5 (Figure 20, Table 3). Fetal NaV1.5-A1330D exhibits a 
significantly larger persistent current and late current density compared to adult NaV1.5-
A1330D. Therefore the functional consequences of A1330D expressed in the fetal NaV1.5 are 
more severe and channel dysfunction is consistent with cardiac arrhythmia predisposition. 
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Figure 20: SCN5A mutations associated with early and later onset of LQTS exhibit 
differential late current densities in the canonical and fetal NaV1.5. 
(A) Averaged tetrodotoxin (TTX)-sensitive currents for WT and mutant canonical NaV1.5 
channels were normalized to the peak current measured at -30 mV during a 200 ms 
depolarization to illustrate persistent current. (B) Averaged tetrodotoxin (TTX)-sensitive 
currents for WT and mutant fetal NaV1.5 channels. (C) Averaged tetrodotoxin (TTX)-sensitive 
late current densities for WT and mutant canonical NaV1.5 channels were normalized to the 
capacitance measured for each cell at -30 mV during a 200 ms depolarization. (D) Averaged 
tetrodotoxin (TTX)-sensitive late current densities for WT and mutant fetal NaV1.5 channels. 
Summary data are provided in Table 3. 
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Table 3: Persistent TTX- sensitive sodium current measured at -30mV for WT and 
SCN5A mutations  
 Persistent Current % 
Current 
Density 
(pA/pF) 
n 
 
Persistent 
Current % 
Current 
Density 
(pA/pF) 
n 
WT NaV1.5 0.2 + 0.04 0.6 ± 0.1 10 Fetal Nav1.5 0.3 ± 0.1 0.4 ± 0.2 10 
NaV1.5- 
L409P/R558 1.4 + 0.2
 b 2.5 ± 0.9 b 7 Fetal Nav1.5-L409P/R558 11.1 + 1.5 
bde 4.4 ± 1.2 bde 10 
NaV1.5-F1473C 1.5 ± 0.3 b 3.4 ± 0.5 b 7 Fetal NaV1.5-F1473C 1.9 ± 0.6 bd 3.2 ± 1.0 bd 7 
NaV1.5-A1330D 0.9 ± 0.1 b 4.9 ± 0.8 b 8 Fetal NaV1.5-A1330D 1.7 ± 0.2 bde 5.8 ± 1.2 bd 10 
NaV1.5-R1623Q 0.5 ± 0.1 0.8 ± 0.1  6 Fetal NaV1.5-R1623Q 0.4 ± 0.04 0.9 ± 0.4 8 
NaV1.5-delKPQ 1.2 ± 0.2 b 1.7 ± 0.4 b 6 Fetal NaV1.5-delKPQ 2.1 ± 0.4 bde 1.0 ± 0.3  9 
   a P< 0.05 compared to WT NaV1.5   
   b P < 0.01 compared to WT NaV1.5 
   c P< 0.05 compared to WT Fetal NaV1.5   
   d P < 0.01 compared to WT Fetal NaV1.5 
   e P < 0.05 compared to NaV1.5-mutant  
 (One Way ANOVA & Bonferroni)   
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 We also compared current density, voltage-dependence of activation, and inactivation 
of A1330D expressed in the adult and fetal NaV1.5 (Figure 21, Table 4). Compared to WT 
channels, we observed that fetal NaV1.5-A1330D exhibited a significant +14 mV shift in the V1/2 
of the voltage-dependence of inactivation (Figure 21C) and significantly slower inactivation 
kinetics vs WT channels (Figure 22). No significant effects on current density or voltage-
dependence of activation were observed (Figure 21A & B). 
 We also measured recovery from inactivation of WT and A1330D channels. Adult 
NaV1.5-A1330D exhibits a significantly faster recovery from inactivation compared to WT 
channels with 22% recovery at 1 ms. However, A1330D expressed in fetal NaV1.5 also 
resulted in ultra-rapid recovery from inactivation with 34% recovery at 1 ms vs WT (Figure 
21D, Table 4).  This is consistent with the observation that A1330D expressed in the fetal 
splice isoform exhibits destabilization of the inactivated state and resembles functional 
consequences observed for fetal NaV1.5-L409P (Chapter II).  
 
Functional consequences of early onset LQT3 mutations F1473C and R1623Q in fetal NaV1.5 
We have shown previously that two early-onset LQTS-associated de novo SCN5A 
mutations (L409P and A1330D) exhibited more severe functional consequences in the fetal 
isoform of NaV1.5. Therefore we chose to investigate the effects of two other SCN5A 
mutations, R1623Q and F1473C. The clinical presentations of these two mutations have been 
previously reported.48,49,64 The SCN5A mutation, R1623Q, was initially discovered in a 
Japanese infant with severe, sporadic LQTS, but has also been described in other reports.49,64  
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Figure 21: Fetal NaV1.5-A1330D and NaV1.5-A1330D exhibit a more depolarized voltage-
dependence of inactivation and a faster recovery from inactivation vs WT. 
(A) Current density-voltage relationships recorded from cells expressing either WT NaV1.5 (n = 
10), NaV1.5-A1330D (n = 8), WT fetal NaV1.5 (n = 10), or fetal NaV1.5-A1330D (n = 14) 
channels (voltage protocol in the inset). (B) Conductance-voltage relationships for WT and 
mutant channels. (C) Steady-state voltage dependence of inactivation for WT and mutant 
channels (n = 9-12). In (B) and (C) lines represent average fits of the data with Boltzmann 
functions. (D) Time course of recovery from inactivation recorded using the illustrated voltage 
protocol. Biophysical fit parameters for all experiments are provided in Table 4. 
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Table 4: Biophysical parameters for WT and mutant NaV1.5 channels expressed in either 
adult or fetal splice isoform 
Voltage-Dependence of Activation  
V 1/2  (mV) k (mV) n  V 1/2  (mV) k (mV) n 
WT NaV1.5 -46.2 ± 2.3 6.6 ± 0.5  10 WT Fetal NaV1.5 -40.5 ± 1.1 a 7.9 ± 0.3 a 10 
NaV1.5-L409P/R558 -39.7 ± 2.9 a 8.9 ± 0.3 b 10 Fetal NaV1.5-L409P/R558 -20.8 ± 1.5  bde 11.0 ± 0.5	  bde	   10 
NaV1.5-R1623Q -44.7 ± 1.7 8.0 ± 0.5 a 9 Fetal NaV1.5-R1623Q -41.0 ± 2.7 7.6 ± 0.5 a 10 
NaV1.5-F1473C -33.8 ± 3.2 b 9.9 ± 0.7 b 6 Fetal NaV1.5-F1473C -33.3 ± 1.2 9.1 ± 0.3 b 10 
NaV1.5-A1330D -41.9 ± 3.0 7.9 ± 0.6 a 8 Fetal NaV1.5-A1330D -41.0 ± 1.5 7.4 ± 0.6 a 14 
NaV1.5-delKPQ -25.1 ± 1.2 b 10.9 ± 0.4 b 12 Fetal NaV1.5-delKPQ -22.2 ± 1.6 bd 11.7 ± 0.2  bd 9 
Voltage-Dependence of Inactivation  
V 1/2  (mV) k (mV) n  V 1/2  (mV) k (mV) n 
WT NaV1.5 -102.7 ± 1.1  -8.5 ± 0.2 12 WT Fetal NaV1.5 -104.1 ± 1.0 -9.0 ± 0.2 10 
NaV1.5-L409P/R558 -93.9 ± 1.6 b -7.6 ± 0.2 11 Fetal NaV1.5-L409P/R558 -85.3 ± 1.1 bde -9.0 ± 0.5 12 
NaV1.5-R1623Q -124.3 ± 1.9 b -11.8 ± 0.9 b 9 Fetal NaV1.5-R1623Q -119.7 ± 1.3 bd -11.0 ± 0.4  bd 12 
NaV1.5-F1473C -99.0 ± 0.9 -7.9 ± 0.9 6 Fetal NaV1.5-F1473C -99.9 ± 0.9 -6.6 ± 0.2  bd 9 
NaV1.5-A1330D -94.6 ± 3.3 b -6.0 ± 0.3 a 9 Fetal NaV1.5-A1330D -89.6 ± 1.6  bd -6.0 ± 0.3  bd 10 
NaV1.5-delKPQ -116.7 ± 1.4 b -8.3 ± 0.6 9 Fetal NaV1.5-delKPQ -112.8 ± 3.0  bd -10.4 ± 0.8  bd 10 
 Recovery from Inactivation (-120mV) 
 τ (msec) n  τ (msec) n 
WT NaV1.5 12.0 ± 1.0 10 WT Fetal NaV1.5 12.0 ± 1.4 10 
NaV1.5-L409P/R558 1.4 ±	  0.1 b	   8 Fetal NaV1.5-L409P/R558 1.2 ± 0.1 bd	   4 
NaV1.5-R1623Q 12.1 ± 1.0 9 Fetal NaV1.5-R1623Q 8.3 ± 0.6 ace 7 
NaV1.5-F1473C 3.0 ± 0.3 b 6 Fetal NaV1.5-F1473C 3.0 ± 0.2  bd 9 
NaV1.5-A1330D 3.6 ± 0.4 b 7 Fetal NaV1.5-A1330D 2.2 ± 0.2  bd 7 
NaV1.5-delKPQ 6.5 ± 0.4 b 11 Fetal NaV1.5-delKPQ 10.0 ± 1.4 e 8 
   a P< 0.05 compared to WT NaV1.5   
   b P < 0.01 compared to WT NaV1.5 
   c P< 0.05 compared to WT Fetal NaV1.5   
   d P < 0.01 compared to WT Fetal NaV1.5 
   e P < 0.05 compared to NaV1.5-mutant  
 (One Way ANOVA & Bonferroni)   
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Figure 22: Inactivation kinetics of WT and mutant sodium channels. 
(A) Time constants of inactivation for WT and mutant sodium channels in the adult NaV1.5 
splice variant (n = 6-8). NaV1.5-R1623Q exhibits significantly slower inactivation vs WT at all 
voltages (-30 to +20 mV). NaV1.5-A1330D exhibits significantly slower inactivation vs WT at -
30 mV. (B) Time constants of inactivation for WT and mutant sodium channels in the fetal 
NaV1.5 splice variant (n = 6-8). Fetal NaV1.5-R1623Q exhibits significantly slower inactivation 
vs WT fetal NaV1.5 at all voltages (-30 to +20 mV). Fetal NaV1.5-A1330D exhibits significantly 
slower inactivation vs WT from -20 to +20 mV. Fetal NaV1.5-delKPQ exhibits significantly 
slower inactivation vs WT fetal NaV1.5 at all voltages (-30 to +20 mV). Values were derived 
from single exponential fits to the decay phase of the current. Statistical significance was 
determined at the p < 0.05 level by Student t-test for a given voltage. 
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Mutation SCN5A-F1473C was discovered in a newborn of Italian and Portuguese 
ancestry who presented with fetal bradycardia followed by extreme QT prolongation, 2:1 AV 
block, and recurrent episodes of torsades de pointes in early infancy.48 Mutation SCN5A-
F1473C has been shown to evoke a significant increase in persistent sodium current 
compared to WT channels when expressed in the adult isoform of NaV1.5.48 We have 
investigated the effects of F1473C on the fetal splice variant of NaV1.5 and compared these 
effects to F1473C expressed in adult NaV1.5. Adult NaV1.5-F1473C evoked a 7.5-fold greater 
persistent sodium current (1.5 ± 0.3%) and a 5.7-fold greater late current density (3.4 ± 0.5 
pA/pF) vs WT. However, fetal NaV1.5-F1473C also evoked a 6.3-fold increase in the level of 
persistent sodium current (1.9 ± 0.6%) and an 8-fold greater late current density (3.2 ± 1.0 
pA/pF) compared to WT fetal NaV1.5 (Figure 20, Table 3). Therefore the functional 
consequences F1473C in the fetal splice variant are similar to those observed in the adult 
background. 
 We also compared current density, voltage-dependence of activation, inactivation, and 
recovery from inactivation of F1473C expressed in the adult and fetal NaV1.5 (Figure 23, Table 
4). Fetal NaV1.5-F1473C significantly shifted the V1/2 of voltage-dependence of activation +8 
mV compared to WT fetal NaV1.5. No significant effects on current density, voltage-
dependence of inactivation, or inactivation kinetics were observed (Figure 23A & 3C, Figure 
22, Table 4). Furthermore, both adult and fetal NaV1.5-F1473C exhibited a significantly faster 
recovery from inactivation with 23% recovery at 1 ms compared to WT channels (Figure 23D, 
Table 4).  Here we have shown that SCN5A-F1473C has the same functional effects when 
expressed in either the adult or fetal isoform of NaV1.5. 
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Figure 23: Fetal NaV1.5-F1473C and NaV1.5-F1473C exhibit a more depolarized voltage-
dependence of activation and a faster recovery from inactivation vs WT.  
(A) Current density-voltage relationships recorded from cells expressing either WT NaV1.5 (n = 
10), NaV1.5-F1473C (n = 6), WT fetal NaV1.5 (n = 10), or fetal NaV1.5-F1473C (n = 10) 
channels (voltage protocol in the inset). (B) Conductance-voltage relationships for WT and 
mutant channels. (C) Steady-state voltage dependence of inactivation for WT and mutant 
channels (n = 6-12). In (B) and (C) lines represent average fits of the data with Boltzmann 
functions. (D) Time course of recovery from inactivation recorded using the illustrated voltage 
protocol. Biophysical fit parameters for all experiments are provided in Table 4. All wild-type 
data is the same as in Figure 21.  
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 Additionally, we compared the functional effects of SCN5A-R1623Q expressed in 
canonical and fetal NaV1.5 (Figure 24). Previous reports have shown that NaV1.5-R1623Q 
does not evoke a significant increase in persistent current typical of most LQT3 mutations. 
Rather, NaV1.5-R1623Q exhibits slowed activation and inactivation kinetics.64 We have 
confirmed these observations in the adult isoform. However, fetal NaV1.5-R1623Q also 
exhibited significantly slower activation rise times and significantly slower inactivation kinetics 
vs WT fetal channels. Although not statistically significant, fetal NaV1.5-R1623Q exhibited even 
slower activation rise times and inactivation kinetics compared to R1623Q expressed in the 
adult isoform of NaV1.5 (Figure 22 & 25).  
 We also compared current density, voltage-dependence of activation, inactivation, and 
recovery from inactivation of R1623Q expressed in the adult and fetal NaV1.5. Fetal NaV1.5-
R1623Q exhibited a -15 mV shift in the V1/2 of voltage-dependence of inactivation vs WT 
(Figure 24C, Table 4). Fetal NaV1.5-R1623Q exhibits a significantly faster recovery from 
inactivation compared to WT and canonical NaV1.5 mutant channels (Figure 24D, Table 4). 
However, this effect was not observed for adult NaV1.5-R1623Q and was not as ultra-rapid as 
the other early-onset LQT3 mutations. No significant effects on current density or voltage-
dependence of activation were observed (Figure 24A & B). Mutation SCN5A-R1623Q also 
exhibited similar functional effects when expressed in either isoform of NaV1.5. 
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Figure 24: Fetal NaV1.5-R1623Q exhibits a faster recovery from inactivation compared to 
NaV1.5-R1623Q and WT channels. 
(A) Current density-voltage relationships recorded from cells expressing either WT NaV1.5 (n = 
10), NaV1.5-R1623Q (n = 9), WT fetal NaV1.5 (n = 10), or fetal NaV1.5-R1623Q (n = 10) 
channels (voltage protocol in the inset). (B) Conductance-voltage relationships for WT and 
mutant channels. (C) Steady-state voltage dependence of inactivation for WT and mutant 
channels (n = 9-12). In (B) and (C) lines represent average fits of the data with Boltzmann 
functions. (D) Time course of recovery from inactivation recorded using the illustrated voltage 
protocol. Biophysical fit parameters for all experiments are provided in Table 4. All wild-type 
data is the same as in Figure 21.  
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Figure 25: R1623Q channels exhibit slower time to peak vs WT. 
Time to peak for WT and mutant R1623Q sodium channels in the adult and fetal NaV1.5 splice 
variant (n = 6-8). NaV1.5-R1623Q exhibited significantly slower time to peak vs WT at all 
voltages (-40 to +20 mV). Fetal NaV1.5-R1623Q exhibited significantly slower time to peak vs 
WT at all voltages (-40 to +40 mV). Statistical significance was determined at the p < 0.05 level 
by Student t-test for a given voltage.  
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Functional consequences of a typical LQT3 mutation delKPQ expressed in fetal NaV1.5  
 Some SCN5A mutations associated with LQT3 are rarely observed in early life and are 
associated with a more typical onset of QT prolongation in early adolescence to 
adulthood.72,111,114–116 We hypothesized that fetal NaV1.5 may exhibit protective or mask the 
effects for SCN5A mutations associated with a more typical age of onset such as delKPQ. To 
test this hypothesis, we expressed delKPQ in the fetal NaV1.5 in heterologous cells and 
compared the functional effects to adult NaV1.5-delKPQ.  
 We compared current density, voltage-dependence of activation, inactivation, and 
recovery from inactivation of delKPQ expressed in the adult and fetal NaV1.5 (Figure 26, Table 
4).  Fetal NaV1.5-delKPQ exhibited a greater reduction in current density vs WT channels and 
shifted peak current density +20 mV (Figure 26A). Additionally, fetal NaV1.5-delKPQ exhibited 
depolarized shifts in the V1/2 of the voltage-dependence of activation. NaV1.5-delKPQ exhibited 
a significantly faster recovery from inactivation than fetal NaV1.5-delKPQ and WT channels 
(Figure 26D, Table 4). Furthermore, adult and fetal NaV1.5-delKPQ exhibited hyperpolarized 
shifts in the V1/2 of the voltage-dependence of inactivation compared to WT channels.    
 NaV1.5-delKPQ evoked a 6-fold greater persistent sodium current (1.2 ± 0.2%) and a 
2.8-fold greater late current density (1.7 ± 0.4 pA/pF) vs WT (Figure 20, Table 3). Although 
fetal NaV1.5-delKPQ exhibited a 7-fold greater persistent sodium current (2.1 ± 0.4%) 
compared to WT channels, late current density was not significantly increased (Figure 20, 
Table 3). The dramatic reduction in current density and the late current density of fetal NaV1.5-
delKPQ suggests an overall loss of function by fetal NaV1.5-delKPQ channels compared to  
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Figure 26: Fetal NaV1.5-delKPQ exhibits a dramatic reduction in current density and 
slower recovery from inactivation compared to NaV1.5-delKPQ.  
(A) Current-voltage relationships for WT, NaV1.5-delKPQ, and fetal NaV1.5-delKPQ channels 
(n = 9-12). Current was normalized to cell capacitance to give a measure of current density. 
(B) Conductance-voltage (right y-axis) relationships for WT and mutant channels. Lines 
represent average fits of the data with Boltzmann functions. (C) Superimposed curves 
representing the voltage-dependence of steady-state inactivation. (D) Time course of recovery 
from inactivation recorded using the illustrated voltage protocol. Biophysical fit parameters for 
all experiments are provided in Table 4. All wild-type data is the same as in Figure 21.  
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adult NaV1.5-delKPQ. These functional effects may be responsible for the later onset of LQT3 
as expression of canonical NaV1.5 increases after birth in human heart.52  
 
SCN5A mutations exhibit ultra-fast recovery from inactivation and sodium channel dysfunction 
during pulse trains 
 The early onset LQT3 mutations, A1330D and F1473C, elicited ultra-fast recovery from 
inactivation that was similar to that observed for L409P/R558 previously described in Chapter 
II.  Therefore, we investigated whether the early onset LQT3 mutations would also exhibit ultra-
fast recovery when channels were inactivated at more extreme voltages of -140 or -90 mV 
using a similar 50 ms recovery protocol as shown in the Figure 26D inset (Figure 27, Table 5). 
NaV1.5-A1330D channels exhibited an ultra-fast recovery from inactivation at -140 mV (1.4 ± 
0.1 ms) and -90 mV (15.8 ± 2.1 ms) compared to WT NaV1.5 (-140 mV: 2.6 ± 0.3 ms, -90mV: 
68.7 ± 3.2 ms) (Figure 27A). Fetal NaV1.5-A1330D channels exhibited a significantly faster 
recovery from inactivation with smaller time constants at -140 mV (1.3 ± 0.1 ms) and -90 mV 
(17.9 ± 6.3 ms) compared to WT fetal NaV1.5 (-140 mV: 3.3 ± 0.4 ms, -90 mV: 49.7 ± 5.9 ms) 
(Figure 27B). These results demonstrate that A1330D channels exhibit an ultra-rapid recovery 
mechanism compared to WT channels in the fetal or adult NaV1.5 at the more extreme 
voltages.   
 In addition, NaV1.5-F1473C channels exhibited an ultra-fast recovery from inactivation 
at -140 mV (1.6 ± 0.1 ms) and -90 mV (16.2 ± 2.3 ms) compared to WT NaV1.5 (-140 mV: 2.6 ± 
0.3 ms, -90mV: 68.7 ± 3.2 ms) (Figure 27A). Fetal NaV1.5-F1473C channels exhibited a 
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Figure 27: Recovery time constants for WT and mutant NaV1.5 channels. 
(A) Recovery time constants for WT and mutant adult NaV1.5 channels shown at -140, -120, 
and -90 mV. (B) Recovery time constants for WT and mutant fetal NaV1.5 channels shown at -
140, -120, and -90 mV. The recovery time constant values and statistical comparisons for WT 
and mutant channels at -140 and -90 mV are shown in Table 5.  
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Table 5: Recovery time constants for WT and mutant NaV1.5. 
 Recovery from Inactivation (-140 mV) 
 τ (msec) n  τ (msec) n 
WT NaV1.5 2.6 ± 0.3 5 WT Fetal NaV1.5 3.3 ± 0.4 5 
NaV1.5-L409P/R558 1.6 ± 0.1 5 Fetal NaV1.5-L409P/R558 1.3 ± 0.2 ac 5 
NaV1.5-R1623Q 3.8 ± 0.3 5 Fetal NaV1.5-R1623Q 3.2 ± 0.6 5 
NaV1.5-F1473C 1.6 ± 0.1 5 Fetal NaV1.5-F1473C 1.7 ± 0.6 c 5 
NaV1.5-A1330D 1.4 ± 0.1 a 5 Fetal NaV1.5-A1330D 1.3 ± 0.1 ad 5 
NaV1.5-delKPQ 4.2 ± 0.3 5 Fetal NaV1.5-delKPQ 2.6 ± 0.3 5 
 Recovery from Inactivation (-90 mV) 
 τ (msec) n  τ (msec) n 
WT NaV1.5 68.7 ± 3.2  5 WT Fetal NaV1.5 49.7 ± 5.9 5 
NaV1.5-L409P/R558 17.4 ± 3.4 b 5 Fetal NaV1.5-L409P/R558 9.0 ± 0.6 bd 5 
NaV1.5-R1623Q 12.2 ± 1.2 b 5 Fetal NaV1.5-R1623Q 19.8 ± 4.3 bd 5 
NaV1.5-F1473C 16.2 ± 2.3 b 5 Fetal NaV1.5-F1473C 11.5 ± 4.1 bd 5 
NaV1.5-A1330D 15.8 ± 2.1 b 5 Fetal NaV1.5-A1330D 17.9 ± 6.3 bd 5 
NaV1.5-delKPQ 3.0 ± 1.0 b 3 Fetal NaV1.5-delKPQ 13.9 ± 1.9 bde 5 
   a P< 0.05 compared to WT NaV1.5   
   b P < 0.01 compared to WT NaV1.5 
   c P< 0.05 compared to WT Fetal NaV1.5   
   d P < 0.01 compared to WT Fetal NaV1.5 
   e P < 0.05 compared to NaV1.5-mutant  
 (One Way ANOVA & Bonferroni)   
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significantly faster recovery from inactivation with smaller time constants at -140 mV (1.7 ± 0.5 
ms) and -90 mV (11.5 ± 4.1 ms) compared to WT fetal NaV1.5 (-140 mV: 3.3 ± 0.4 ms, -90 mV: 
49.7 ± 5.9 ms) (Figure 27B). These results demonstrate that F1473C channels exhibit an ultra-
rapid recovery mechanism compared to WT channels in the fetal or adult NaV1.5 as well. 
Typical onset LQT3 mutation delKPQ, exhibits a significantly faster recovery from inactivation 
but only at -90 mV in the adult NaV1.5 (3.0 ± 1.0 ms) and fetal NaV1.5 (13.9 ± 1.9 ms). 
However, the acceleration was much less dramatic for fetal NaV1.5-delKPQ compared to 
delKPQ expressed in the adult isoform of the channel. 
 We also investigated whether repeated stimulation of mutant sodium channels would 
result in attenuated or enhanced loss of channel availability compared to WT channels. Cells 
were pulsed at frequencies of 1 or 2 Hz and sodium currents were normalized to the first pulse. 
It is important to note that the frequency of 2 Hz is similar to the fetal heart rate (~120 bpm) 
while a frequency of 1 Hz is similar to an adult heart rate (~60 bpm).106,107 However these 
recording were performed at room temperature. NaV1.5-A1330D and fetal NaV1.5-A1330D 
both exhibited a significantly enhanced loss of channel availability at 1 and 2 Hz (Figure 28 & 
Figure 29). Furthermore, NaV1.5-F1473C and fetal NaV1.5-F1473C both exhibited a 
significantly enhanced loss of channel availability at 1 and 2 Hz (Figure 28 & 29). Typical onset 
mutation, delKPQ did not exhibit significant attenuation or enhanced loss of channel 
availability. This mutation exhibited effects more similar to WT channels upon frequent 
stimulation at 1 and 2 Hz. These results further suggest that early onset LQT3 mutations 
exhibit similar or more severe functional effects in the fetal splice variant compared to the adult 
NaV1.5.  
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Figure 28: Pulse trains of WT and mutant NaV1.5 channels at a frequency of 1 Hz.  
(A) WT and mutant adult NaV1.5 channels (n = 4-6). (B) WT and mutant fetal NaV1.5 channels 
(n = 4-6). Statistical significance was assumed as P < 0.05 by Student’s t-test.  
 
Figure 29: Pulse trains of WT and mutant NaV1.5 channels at a frequency of 2 Hz.  
(A) WT and mutant adult NaV1.5 channels (n = 4-6). (B) WT and mutant fetal NaV1.5 channels 
(n = 4-6). Statistical significance was assumed as P < 0.05 by Student’s t-test.  
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Discussion 
 The three perinatal SCN5A mutations investigated encode dysfunctional cardiac sodium 
channels that exhibit persistent sodium current or impaired inactivation kinetics (R1623Q) but 
the degree of channel dysfunction determined in the context of the canonical adult NaV1.5 
splice product did not fully explain the unusual severity and early onset of LQTS in these 
cases. It has been reported that SCN5A undergoes developmentally-regulated alternative 
mRNA splicing to generate multiple isoforms of the protein.88 Previously, we have shown that 
fetal NaV1.5 is highly expressed in human fetal and neonatal hearts and that one SCN5A 
mutation associated with a severe fetal arrhythmia, L409P, exhibited more severe functional 
consequences in the context of fetal splice isoform of NaV1.5 (Chapter II).52  
 Hence, we investigated the functional consequences of the three additional SCN5A 
mutations in the fetal NaV1.5 splice isoform- A1330D, F1473C, and R1623Q. We also 
compared the functional effects of these early onset LQT3 mutations with that of a more typical 
onset LQT3 mutation, delKPQ. These experiments indicated that SCN5A-A1330D conferred 
much greater functional defects on fetal NaV1.5 than when expressed in the adult NaV1.5. 
Specifically, the proportion of persistent current was greater for fetal NaV1.5-A1330D (1.7 ± 
0.2%) compared to adult NaV1.5-A1330D (0.9 ± 0.1%). This was accompanied with a 
significant increase in the late current density (Figure 20, Table 3). In addition, SCN5A-
A1330D exhibited many other functional defects in the fetal NaV1.5 such as a depolarized shift 
in the voltage-dependence of inactivation (Figure 21C), significantly slower inactivation kinetics 
(Figure 22), and an ultra-fast recovery from inactivation compared to WT channels (Figure 
21D).   
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 We also demonstrated that expression of F1473C and R1623Q in the fetal splice variant 
of NaV1.5 mirrored the effects of the mutation in the adult background. Specifically, SCN5A-
F1473C exhibited greater persistent sodium current in both the adult NaV1.5 (1.5 ± 0.3%) and 
fetal NaV1.5 (1.9 ± 0.6%) compared to WT channels (Figure 20, Table 3). Furthermore, 
F1473C exhibited ultra-fast recovery from inactivation (Figure 23D) that was also observed for 
SCN5A-L409P/R558 and SCN5A-A1330D, two other early onset LQTS mutations. Mutation 
SCN5A-R1623Q exhibited significantly slower inactivation kinetics in the adult and fetal NaV1.5 
compared to WT channels (Figure 22). The inactivation time constants for fetal NaV1.5-
R1623Q was slower than R1623Q expressed in the adult isoform. However, this was not 
statistically significant. Therefore, in the neonatal heart, where the expression ratio of fetal to 
adult mRNA is ~1:1,52 mutant F1473C and R1623Q channels are severely dysfunctional in 
both backgrounds of the sodium channel.  
 In addition to these findings, we demonstrated that A1330D and F1473C channels 
exhibited an ultra-fast recovery from inactivation, a similar observation we made for L409P. 
Fetal NaV1.5-A1330D exhibited an even faster recovery than A1330D in the adult background. 
However, pulse train experiments revealed that these mutations (A1330D and F1473C) result 
in an enhanced loss of channel availability following repeated stimulation. By contrast, R1623Q 
and delKPQ did not exhibit an ultra-fast recovery from inactivation when expressed in the fetal 
NaV1.5 and had no significant effect on channel availability during pulse trains. We further 
investigated the recovery from inactivation at -140 and -90 mV to determine whether mutant 
channels were also dysfunctional at these extreme voltages. At -90 mV all mutant channels 
exhibited a significantly faster recovery from inactivation vs WT channels. However, the 
acceleration for delKPQ in the fetal splice variant was not as severe compared to adult NaV1.5-
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delKPQ (Figure 27, Table 5). We speculate that sodium channels with an ultra-rapid recovery 
mechanism that was observed for the early onset LQT3 mutations, may prime the 
cardiomyocyte for re-activation during ventricular repolarization in some cases. It is feasible 
that recovery from inactivation may be an important biophysical property in the immature heart 
especially under pathophysiological conditions such as re-entrant arrhythmias. However, 
further investigation of the molecular mechanism of mutant fetal NaV1.5 in native 
cardiomyocytes or induced pluripotent cardiomyocytes (iPS-CMs) is required to determine if 
ultra-fast recovery from inactivation is pathological. Single channel recordings of fetal NaV1.5-
A1330D and fetal NaV1.5-F1473C compared to WT channels may also provide further insight 
to the mechanism of enhanced loss of channel availability in addition to the ultra-fast recovery 
from inactivation observed for these mutations.  
 Here we have also compared the effects of SCN5A-delKPQ with that of the three early 
onset LQT3 mutations. Our rationale for investigating the effects of SCN5A-delKPQ in the fetal 
NaV1.5 was that LQTS patients with SCN5A-delKPQ rarely present with an arrhythmia in early 
life (fetal – infancy) when expression of the fetal splice isoform is prominent.115–117 Previous 
studies investigating the functional effects of delKPQ in tsA201 cells were performed using a 
different sodium channel background called hH1. The hH1 plasmid does not express the 
common variant arginine that is present at position 1027. Instead, hH1 expresses a glutamine 
that is considered to be a rare variant. In addition, the internal solutions used in the previous 
study contained 10 mM EGTA where our solution contained 2 mM EGTA.118 This may change 
the concentration of free local calcium that has been shown to result in changes in the voltage-
dependence of inactivation (also see Chapter IV). Therefore, these changes in the methods 
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may be responsible for the differences in the observed shifts in the voltage-dependence of 
activation and inactivation for NaV1.5-delKPQ.   
   When we expressed delKPQ in the fetal NaV1.5, there was an attenuated gain of 
function compared to adult NaV1.5-delKPQ channels. Fetal NaV1.5-delKPQ exhibited a 
significant reduction in current density (Figure 26A) and late current density (Figure 20, Table 
3) compared to adult NaV1.5-delKPQ. In this case, the functional effects of fetal NaV1.5-
delKPQ may be responsible for the later onset of cardiac events in patients with this mutation. 
In addition, adult or fetal NaV1.5-delKPQ did not exhibit a significant change in channel 
availability during pulse trains compared with WT and early onset LQT3 mutations 
(L409P/R558, A1330D, and F1473C). Overall, the biophysical effects of SCN5A mutations 
expressed in the fetal NaV1.5 may be a distinguishing factor in the timing of the onset and 
severity of LQTS.  
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CONCLUSIONS 
 
 In summary, we have shown that SCN5A mutations associated with some perinatal 
forms of LQTS (R1623Q, F1473C, and A1330D) exhibit more severe or similar functional 
consequences in the fetal NaV1.5 compared to their expression in the canonical adult splice 
variant. By contrast, typical onset mutation, delKPQ demonstrated an attenuated gain of 
function in fetal NaV1.5 but this was not observed when delKPQ was expressed in the 
canonical adult NaV1.5. Our findings implicate dysfunction of a fetal-expressed sodium channel 
splice isoform as a distinguishing factor for early onset LQT3 compared to later onset 
arrhythmias. These studies are highly important for determining the molecular mechanism for 
severe arrhythmias that manifest in the earliest stages of development.  
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CHAPTER IV 
 
Arrhythmogenic Calmodulin Mutations Disrupt Intracellular Cardiomyocyte Ca2+ 
Regulation by Distinct Mechanisms  
 
INTRODUCTION 
 
 Congenital long QT syndrome (LQTS) and catecholaminergic polymorphic ventricular 
tachycardia (CPVT) are two forms of genetic disorders of heart rhythm that may present during 
childhood and cause life-threatening cardiac arrhythmias.119 The molecular mechanisms 
underlying arrhythmia susceptibility have been inferred from studies of mutant gene products, 
which are largely ion channels or channel regulators. In LQTS, loss-of-function of potassium 
channels or gain-of-function in either sodium or calcium channels represent the major 
molecular mechanisms.17 In contrast to disturbances in plasma membrane ion channel 
function, CPVT arises from disordered intracellular Ca2+ regulation most frequently because of 
mutation of the ryanodine receptor Ca2+-release channel of the sarcoplasmic reticulum. These 
advances have improved our understanding of arrhythmogenesis and have revealed new 
therapeutic targets.  
 Recently, recurrent cardiac arrest in infants with a severe form of LQTS were 
discovered to have mutations in CALM1 (D130G, F142L) or CALM2 (D96V, D132E, and 
D134H), two genes encoding the ubiquitous Ca2+ signaling protein calmodulin (CaM).92 
Independently, two distinct CaM mutations (N54I, N98S) were discovered in subjects with a 
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CPVT-like syndrome although one of these mutations (N98S) has also been identified in a 
subject with LQTS.120 In addition, another CALM1 mutation, F90L, was identified in a family 
with idiopathic ventricular tachycardia and sudden death in adolescence.121 There are three 
CALM genes (CALM1, CALM2, CALM3) that encode the same CaM protein.92 However, the 
regulation of their expression is still being investigated. Most of the mutations described affect 
conserved amino acid residues that are known to participate in Ca2+ binding or in energetic 
coupling of ion binding to CaM activation (Figure 30). Biochemical studies revealed that most 
CaM mutations, except N54I, cause reduced Ca2+ binding affinity.92,122 However, the cellular 
basis for arrhythmogenesis in the setting of CaM mutations has not been elucidated.   
 Calmodulin controls a large number of enzymes, ion channels and other proteins.123,124 
In cardiomyocytes, key CaM interacting proteins include those critically involved in beat-to-beat 
Ca2+ homeostasis. CaM interacts with the cardiac sodium channel via the C-terminal IQ 
domain or the D3/D4 linker.123–125 Previous studies have shown that the binding interaction of 
CaM to the IQ of NaV1.5 significantly enhances slow inactivation, a channel-gating process 
linked to life-threatening idiopathic ventricular arrhythmias.126 In addition, CaM that is not 
bound to calcium, designated as apo-CaM, has been shown to interact with NaV1.5 by nuclear 
magnetic resonance studies (NMR).125 However the structural biology of the CaM-NaV1.5 
complex has not conclusively determined how CaM affects channel gating. 
 In addition to sodium channel effects, CaM is pre-bound to the cardiac L-type Ca2+ 
channel (LTCC) where it senses local Ca2+ influx and cytosolic Ca2+. The complex of Ca2+-
CaM promotes a rapid inactivation of LTCC Ca2+ current (ICaL).127 This process, known as 
Ca2+-dependent inactivation (CDI) is a major determinant of cardiac contractability.128 
Engineered CaM with carboxyl lobe (C-lobe) mutations abrogating Ca2+-C-lobe binding 
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attenuated CDI and prolonged action potential (AP) duration.128 The majority of the z-line CaM 
also binds to ryanodine receptor 2 (RyR2);128 irrespective of Ca2+ concentrations, CaM inhibits 
RyR2 opening.129,130 Disrupting the CaM-RyR2 complex has multiple effects including 
increased opening of RyR2, diminished ICaL, and increased cytosolic Ca2+ at negative 
membrane potentials which creates a molecular substrate for arrhythmogenic triggers.131 In 
this respect, CPVT and defective CaM-RyR2 function lead to a common endpoint. Whereas 
attenuated CDI evoked by engineered defective CaM prolongs action potential duration that 
could underpin QT interval prolongation.32,33 
 Here we investigated the effects of LQTS-associated CaM mutations on sodium and 
calcium channel currents to elucidate the molecular mechanisms underlying arrhythmia 
predisposition. We also show that CaM mutations had inconsistent effects on sodium channels 
but caused impaired CDI of ICaL in cardiomyocytes. Our findings implicate different molecular 
substrates for arrhythmogenesis associated with CaM mutations.  
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Figure 30: Calmodulin mutations associated with life-threatening cardiac arrhythmias.  
CaM mutations associated with life-threatening cardiac arrhythmias affect conserved amino 
acid residues that are known to participate in Ca2+ binding or in energetic coupling of ion 
binding to CaM activation. Mutations associated with a LQTS phenotype include D96V, 
D130G, D132E, D134H, and F142L. Mutations associated with CPVT are N54I and N98S. The 
idiopathic VT mutation, F90L, (not shown) is located within the linker between EF hand II and 
EF hand III. Figure adapted from Makita et al. (2013).120 
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METHODS 
 
Mutagenesis of calmodulin 
 The mutant calmodulin (CaM) was engineered by making one of the following amino 
acid substitutions: F90L, D96V, D130G, D132E, D134H, F142L. A mammalian expression 
plasmid was used to drive expression of wild-type (WT) or mutant CaM by the immediate early 
CMV promoter along with the coding region for either GFP or CD8 preceded by the IRES2 
element as co-transfection markers.  
 
Heterologous expression of human NaV1.5 with calmodulin 
 Plasmids encoding recombinant human cardiac sodium channel isoforms (NaV1.5) were 
described previously.52 For studies of sodium channel function, wild-type (WT) cardiac sodium 
channel cDNA (0.5 µg) and WT or mutant CaM (F90L, D96V, D130G, D132E, D134H, F142L) 
cDNA (0.5 µg) were transiently transfected into tsA201 cells using FuGene HD (Roche 
Diagnostics, Indianapolis, IN), then incubated for 48 hours at 37°C prior to electrophysiological 
measurements. Cells selected for patch clamp recordings exhibited GFP or CD8 expression 
and were easily distinguishable from non-GFP or CD8 expressing cells.  
 
In vitro electrophysiology of sodium channels  
          Sodium currents were recorded at room temperature using the whole-cell patch clamp 
technique as described previously.52,132 The extracellular bath solution contained the following 
(in mmol/L): 140 NaCl, 4 KCl, 1.8 CaCl2, 1 MgCl2, 10 HEPES, and 10 glucose, pH 7.35 
(adjusted with NaOH). The low calcium intracellular pipette solution contained the following (in 
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mmol/L): 10 NaF, 100 CsF, 20 CsCl, 20 BAPTA, 10 HEPES, 10 glucose, pH 7.35 (adjusted 
with CsOH). The high calcium (~1 µM free) intracellular pipette solution contained the following 
(in mmol/L): 10 NaF, 100 CsF, 20 CsCl, 1 BAPTA, 0.9 CaCl2, 10 HEPES, 10 glucose, pH 7.35 
(adjusted with CsOH).124 Osmolarity was adjusted to 310 mOsm/l with sucrose for the bath 
solution and 300mOsm/l for pipette solution. Data were acquired with an Axopatch 200B 
patch-clamp amplifier and pClamp 10.2 software. Tetrodotoxin (TTX)-sensitive persistent 
current was determined with a 200-ms depolarization to -30 mV as the average current 
recorded between 190 and 200 ms and reported as a percentage of peak current following 
digital subtraction of currents recorded in the presence and absence of 30 µmol/L TTX (Tocris 
Biosciences, Ellisville, MO). Some experiments were performed in the presence of 10 µM KN-
93, a small molecule inhibitor of CAMKII that was added into the intracellular pipette solution. 
All data were analyzed with pClamp 10.2 (Axon Instruments, Inc, Sunnyvale, CA) and plotted 
using Sigmaplot 10.0 (SPSS, Inc, Chicago, IL) software. Results are presented as mean ± 
SEM. For recovery from inactivation, amplitudes (A) are equal to 1.00 ± 0.1. Unless otherwise 
noted, statistical comparisons were made by using a one-way ANOVA and Bonferroni 
correction to WT NaV1.5 co-expressed with WT CaM. Statistical significance was assumed for 
P < 0.05.  
 
In vitro electrophysiology of L-type calcium channels and calcium transient measurements  
 All experimental procedures and protocols were approved by the Animal Care and Use 
Committee of the University of Kentucky, and conformed to the NIH Guide for Care and Use of 
Laboratory Animals. Isolated fetal ventricular mouse cardiomyocytes (FVM) were prepared as 
previously described.33,133 L-type calcium current (ICaL) was measured from FVM cells 
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expressing various CaM constructs in the whole-cell recording mode of the patch-clamp 
technique. This work was done by our collaborators in Jonathan Satin’s laboratory at the 
University of Kentucky.  
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RESULTS 
 
 
Functional effects of LQTS CaM mutants, CALM1-D130G, CALM2-D96V, and CALM1-F142L 
on cardiac sodium channels 
 Because calmodulin is known to regulate cardiac sodium channel inactivation and a 
specific defect in sodium channel inactivation (increased persistent sodium current) occurs in 
LQTS,38 we investigated the effects of LQTS-CaM mutants on heterologously expressed 
NaV1.5 as well as on native sodium current in FVMs. We performed heterologous co-
expression of WT or mutant CaM with human NaV1.5 in tsA201 cells and measured the 
electrophysiological properties of the expressed channels.  When recording sodium current 
with a nominally Ca2+-free intracellular solution (apo-CaM), we did not observe differences in 
the level of persistent sodium current (expressed as a % of peak current) for any of the CaM 
mutations compared to WT CaM. Therefore, we repeated these experiments with elevated 
intracellular calcium (~1 µM free Ca2+) to provide a saturating concentration of calcium to 
promote binding of CaM to NaV1.5.92,124 Furthermore, because of the early age of onset of 
LQTS in the reported probands, we also tested the effects of CaM mutations on a fetal and 
neonatal expressed NaV1.5 splice variant.52  
 Cells co-expressing CaM-D130G with fetal NaV1.5 exhibited 7.5-fold larger persistent 
sodium current (1.5 ± 0.4%) compared to cells co-expressing the fetal splice variant with WT 
CaM (0.2 ± 0.1%; p < 0.05) when recordings were made with high intracellular calcium (Figure 
31).  This greater level of persistent current was not observed when CaM-D130G was co-
expressed with the canonical (adult expressed) splice isoform of NaV1.5 or with low  
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Figure 31: LQTS-CaM mutation effects on persistent sodium current of fetal NaV1.5. 
(A) CaM-D130G evoked increased persistent sodium current with fetal NaV1.5.  Averaged 
TTX-sensitive currents were normalized to the peak current measured at −30mV during a 200 
ms depolarization recorded under high intracellular calcium concentration (see Methods). The 
inset represents the same data plotted on an expanded vertical scale. Summary data are 
provided in Table 6. (B) CaM-D130G has no significant effect on persistent sodium current in 
fetal ventricular cardiomyocytes (FVM). Tetrodotoxin (TTX)-sensitive currents were normalized 
to the peak current measured at −30mV during a 300 ms depolarization recorded under a high 
intracellular calcium concentration (see Methods). The inset represents the same data plotted 
on an expanded vertical scale. 
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intracellular calcium (Table 6). Electrophysiological recordings were also performed expressing 
β1 with NaV1.5 and WT or mutant calmodulin. Fetal NaV1.5 co-expressed with CaM-D130G 
and β1 evoked a greater persistent sodium current (1.4 ± 0.3%) compared to fetal channels 
co-expressed with WT CaM and β1 (0.3 ± 0.1%) under high calcium conditions. In contrast, 
cells co-expressing fetal or canonical NaV1.5 splice isoforms with either CaM-D96V or CaM-
F142L did not exhibit abnormal levels of persistent sodium current under high calcium 
conditions (Table 6).  
 Other sodium channel properties including the conductance-voltage relationship, 
voltage dependence of steady-state inactivation, inactivation kinetics, and recovery from 
inactivation were unaffected by CaM mutants (Figure 32, 33, & 34 Table 7). Furthermore, 
expression of CaM-D130G in fetal ventricular mouse cardiac myocytes (FVM) did not evoke 
detectable differences in the level of persistent sodium current compared with cells transfected 
with WT-CaM (Figure 31B). Given the inconsistent effect of CaM mutants on heterologous and 
native sodium current, we concluded that NaV1.5 dysfunction was not the major cause for 
LQTS in the setting of CaM mutations.   
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Table 6: Persistent sodium current in cells expressing WT or mutant CaM. 
 Persistent Current % n 
NaV1.5 + apo-WT CaM 0.3 ± 0.2 4 
NaV1.5 + apo-CaM-D130G 0.2 ± 0.1 4 
NaV1.5 + WT CaM 0.3 ± 0.1 5 
NaV1.5 + CaM-D130G 0.2 ± 0.1 5 
NaV1.5 + CaM-D96V 0.2 ± 0.1 7 
NaV1.5 + CaM-F142L 0.1 ± 0.1 4 
Fetal NaV1.5 + apo-WT CaM 0.4 ± 0.1 6 
Fetal NaV1.5 + apo-CaM-D130G 0.6 ± 0.2 7 
Fetal NaV1.5  + WT CaM 0.2 ± 0.1 9 
Fetal NaV1.5 + CaM-D130G 1.5 ± 0.4*†‡ 13 
Fetal NaV1.5  + WT CaM + KN93 0.1 ± 0.1 7 
Fetal NaV1.5 + CaM-D130G + KN93 0.8 ± 0.2‡ 16 
Fetal NaV1.5 + CaM-D96V 0.4 ± 0.1 8 
Fetal NaV1.5 + CaM-F142L 0.6 ± 0.5 8 
* P < 0.05 compared to NaV1.5 + WT CaM             
† P < 0.05 compared to fetal NaV1.5 + WT CaM 
‡  P < 0.05 compared to fetal NaV1.5 + WT CaM with 10 µM KN-93 
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Figure 32: CaM-D130G does not have significant biophysical effects on peak sodium 
current.  
(A) Representative traces of NaV1.5 or fetal NaV1.5 co-expressed with WT or CaM-D130G. (B) 
Current density-voltage relationships comparing WT and CaM-D130G effects on adult and 
fetal NaV1.5 channels (n = 9-11). (C) Conductance-voltage and steady-state voltage 
dependence of inactivation relationships for adult and fetal NaV1.5 co-expressed with WT or 
CaM-D130G (n = 9-11). Lines represent average fits of the data with Boltzmann functions. (D) 
Recovery from inactivation of NaV1.5 or fetal NaV1.5 co-expressed with WT or CaM-D130G (n 
= 6-10). Biophysical fit parameters for all experiments are provided in Table 7. All experiments 
were preformed under high calcium conditions.  
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Figure 33: CaM-D96V does not have significant biophysical effects on peak sodium 
current.  
(A) Representative traces of NaV1.5 or fetal NaV1.5 co-expressed with WT or CaM-D96V. (B) 
Current density-voltage relationships comparing WT and CaM-D96V effects on adult and fetal 
NaV1.5 channels (n = 9-11). (C) Conductance-voltage and steady-state voltage dependence of 
inactivation relationships for adult and fetal NaV1.5 co-expressed with WT or CaM-D96V (n = 
9-11). Lines represent average fits of the data with Boltzmann functions. (D) Recovery from 
inactivation of NaV1.5 or fetal NaV1.5 co-expressed with WT or CaM-D96V (n = 6-10). 
Biophysical fit parameters for all experiments are provided in Table 7. All experiments were 
preformed under high calcium conditions.  
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Figure 34: CaM-F142L does not have significant biophysical effects on peak sodium 
current.  
(A) Representative traces of NaV1.5 or fetal NaV1.5 co-expressed with WT or CaM-F142L. (B) 
Current density-voltage relationships comparing WT and CaM-F142L effects on adult and fetal 
NaV1.5 channels (n = 9-10). (C) Conductance-voltage and steady-state voltage dependence of 
inactivation relationships for adult and fetal NaV1.5 co-expressed with WT or CaM-F142L (n = 
9-10). Lines represent average fits of the data with Boltzmann functions. (D) Recovery from 
inactivation of NaV1.5 or fetal NaV1.5 co-expressed with WT or CaM-F142L (n = 6-10). 
Biophysical fit parameters for all experiments are provided in Table 7. All experiments were 
preformed under high calcium conditions.  
 
 
 
 
 103	  
Table 7:  CaM mutants do not exhibit major biophysical effects on peak INa. 
 
Biophysical Parameters 
Voltage-Dependence of 
Activation Steady-State Availability 
Recovery From 
Inactivation  
V 1/2  (mV) k (mV) n V 1/2  (mV) k (mV) n τ (msec) n 
NaV1.5 + WT CaM -45.0 ± 2.1 6.6 ± 0.5 9 -102.9 ± 3.2 -8.4 ± 0.2 10 10.9 ± 1.3 6 
NaV1.5 + CaM-D130G -43.1 ± 2.3 6.6 ± 0.5 11 -98.5 ± 1.7 -8.1 ± 0.1 10 8.8 ± 1.1 8 
NaV1.5 + CaM-D96V -42.6 ± 1.1 7.8 ± 0.3 10 -105.2 ± 1.0 -8.7 ± 0.4 13 11.2 ± 0.5 11 
NaV1.5 + CaM-F142L -41.8 ± 2.0 6.7 ± 0.8 10 -96.4 ± 2.2 -8.5 ± 0.4 11 8.7 ± 0.6 10 
Fetal NaV1.5 + WT CaM -38.4 ± 1.7 7.5 ± 0.5 11 -103.3 ± 2.2 -9.7± 1.0 9 9.1 ± 0.8 10 
Fetal NaV1.5 + CaM-D130G -41.0 ± 1.7 7.2 ± 0.5 10 -98.6 ± 1.2 -8.9 ± 0.3 8 11.0 ± 1.3 9 
Fetal NaV1.5 + CaM-D96V -35.2 ± 2.1* 9.4 ± 0.4‡ 9 -99.1 ± 1.4 -13.1 ± 2.3†‡ 9 12.1 ± 1.6 7 
Fetal NaV1.5 + CaM-F142L -35.4 ± 1.7* 8.3 ± 0.6 6 -96.3 ± 1.7 -8.4 ± 0.3 7 8.9 ± 1.4 6 
All recordings were performed with high intracellular calcium concentration 
* P < 0.05 compared to NaV1.5 + WT CaM             
† P < 0.05 compared to fetal NaV1.5 + WT CaM  
‡ P < 0.005 compared to NaV1.5 + WT CaM            
 
 
 
 
 
 
 
 
 
 
 
 
 
 104	  
Persistent current evoked by CaM-D130G on fetal NaV1.5 is not due to CAMKII 
 Previous reports have shown that Ca2+/calmodulin-dependent protein kinase II 
(CAMKII), a downstream effector of CaM, can also evoke persistent sodium currents.123,134,135 
Therefore, we investigated whether the persistent sodium current evoked by D130G was due 
to CAMKII activation by using a small molecule inhibitor of CAMKII, KN-93. In the presence of 
10 µM KN-93, CaM-D130G still evoked an 8-fold increase in the level of persistent sodium 
current (Table 6). This suggests that the persistent sodium current evoked by CaM-D130G on 
fetal NaV1.5 is not due to CAMKII. 
 
Functional effects of CALM2 mutants D132E and D134H on cardiac sodium channels 
 In addition to the three CaM mutations described, two other CALM2 mutations, D132E 
and D134H were later discovered in two more neonatal LQTS cases. Mutation CALM2-D134H 
was identified in a girl who presented at age 19 months with syncope and a long QTc (579 ms) 
followed by several episodes of cardiac arrest. ECG features and treatment responses were 
consistent with LQT3. Mutation CALM2-D132E was discovered by targeted screening of 
CALM1-3 in an adult female of European ancestry with a history of perinatal bradycardia and a 
diagnosis of neonatal LQTS who later exhibited clinical features consistent with CPVT at age 9 
years.120 
 To investigate the functional effects of CaM-D132E and CaM-D134H on NaV1.5, we 
heterologously expressed WT or mutant CaM with human NaV1.5 in tsA201 cells and 
preformed electrophysiological recordings on the expressed channels (Figure 35).  Neither 
mutation had a significant impact on the persistent sodium current of adult or fetal NaV1.5, 
even under high calcium conditions (Table 9).  However, CaM-D134H resulted in significant 
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effects on peak sodium current biophysical parameters such as the voltage-dependence of 
activation, inactivation, and recovery from inactivation under high calcium conditions (Figure 35 
& 36, Table 8).  
 CaM-D134H resulted in a significant hyperpolarized shift in the voltage-dependence of 
activation of adult NaV1.5 compared to expression with WT CaM (Figure 35B).  Furthermore, 
CaM-D134H co-expressed with the fetal NaV1.5 did not result in any changes in the voltage-
dependence of activation (Figure 36B). Additionally, CaM-D134H shifted the voltage-
dependence of inactivation of NaV1.5 to more hyperpolarized potentials vs WT CaM (Figure 
35C). By contrast, CaM-D134H expressed with fetal NaV1.5 resulted in the opposite effect with 
a more depolarized inactivation compared to co-expression with the WT CaM (Figure 36C). 
Furthermore, co-expression of CaM-D134H with the adult NaV1.5 resulted in significant 
slowing of the recovery from inactivation compared to WT CaM (Figure 35D). Interestingly, 
CaM-D134H resulted in a significantly faster recovery from inactivation of the fetal splice 
variant of NaV1.5 (Figure 36D). These results highlight the differential effects of CaM-D134H 
on the adult and fetal isoforms of NaV1.5 suggesting there may be subtle differences in the 
regulation of fetal sodium channels by calmodulin. No significant effects on sodium current 
density were observed (Figure 35A & 36A). Overall, CaM-D132E did not exhibit significant 
effects on either the adult or fetal NaV1.5 peak current (Figure 35 & 36). 
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Figure 35: CaM-D134H results in significant effects on adult NaV1.5 peak current. 
(A) Current-voltage relationships for NaV1.5 and WT CaM, NaV1.5 and CaM-D134H, and 
NaV1.5 and CaM-D132E  (n = 6-7). Current was normalized to cell capacitance to give a 
measure of current density. (B) Conductance-voltage (right y-axis) relationships for sodium 
channels co-expressed with WT or mutant CaM. Lines represent average fits of the data with 
Boltzmann functions. (C) Superimposed curves representing the voltage-dependence of 
steady-state inactivation. (D) Time course of recovery from inactivation recorded using the 
illustrated voltage protocol. Biophysical fit parameters for all experiments are provided in Table 
8.  
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Figure 36: CaM-D134H results in significant effects on fetal NaV1.5 peak current. 
(A) Current-voltage relationships for fetal NaV1.5 and WT CaM, fetal NaV1.5 and CaM-D134H, 
and fetal NaV1.5 and CaM-D132E (n = 6-7). Current was normalized to cell capacitance to give 
a measure of current density. (B) Conductance-voltage (right y-axis) relationships for fetal 
sodium channels co-expressed with WT or mutant CaM. Lines represent average fits of the 
data with Boltzmann functions. (C) Superimposed curves representing the voltage-
dependence of steady-state inactivation. (D) Time course of recovery from inactivation 
recorded using the illustrated voltage protocol. Biophysical fit parameters for all experiments 
are provided in Table 8.  
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Table 8: CaM-D134H results in significant effects on NaV1.5 peak current. 
 
Biophysical Parameters 
Voltage-Dependence of 
Activation Steady-State Availability 
Recovery 
From 
Inactivation 
 
V 1/2  (mV) k (mV) n V 1/2  (mV) k (mV) n τ (msec) n 
NaV1.5 + WT CAM -42.4 ± 1.8 7.9  ± 0.5 7 -103.7 ± 1.2 -8.8 ± 0.4 7 11.5 ± 0.8 7 
NaV1.5 + D134H -49.7 ± 2.1* 7.4 ± 0.4	   7 -113.3 ± 2.0‡ -7.8 ± 0.4 7 14.9 ± 1.4* 6 
NaV1.5 + D132E -45.4 ± 2.2 7.0 ± 0.5 6 -107.7 ± 2.3 8.3 ± 0.2 6 12.1 ±	  1.5	   6 
Fetal NaV1.5 + WT CAM -43.3 ± 1.7 7.4 ± 0.3 7 -102.7 ± 1.7 -8.9 ± 0.3 8 13.8 ±	  1.7 9 
Fetal NaV1.5 + D134H -40.1 ± 2.9	   7.3 ± 1.0 7 -97.6 ± 1.4*† -9.0 ± 0.9	   7 8.1 ±	  1.0*† 7 
Fetal NaV1.5 + D132E -39.9 ± 3.1 8.5 ± 0.9 7 -100.6 ± 1.1 -8.9 ± 0.5 8 9.7 ± 0.8  8 
All recordings were performed with high intracellular calcium concentration 
* P < 0.05 compared to NaV1.5 + WT CAM           ‡ P < 0.005 compared to NaV1.5 + WT CAM            
† P < 0.05 compared to Fetal NaV1.5 + WT CAM 
 
Table 9: There are no significant effects of CaM-D134H or CaM-D132E on persistent INa. 
  
 Persistent Current % n 
NaV1.5 + WT CaM  0.3 ± 0.1	   9 
NaV1.5 + CaM-D134H 0.2 ± 0.1 5 
NaV1.5 + CaM-D132E 0.6 ±0.3 5 
Fetal NaV1.5 + WT CaM  0.4 ± 0.1 14 
Fetal NaV1.5 + CaM-D134H 0.5 ± 0.2 13 
Fetal NaV1.5 + CaM-D132E  0.5 ± 0.2 6 
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Functional effects of idiopathic VT mutation CALM1-F90L on cardiac sodium channels 
 We determined the functional consequences of CaM-F90L on cardiac sodium channel 
function by heterologously co-expressing WT CaM or mutant CaM-F90L with human NaV1.5 in 
tsA201 cells and performed electrophysiological recordings (Figure 37A). Under usual 
conditions for recording sodium current in tsA201 cells, which involves a nominally calcium-
free intracellular solution, we did not observe differences in the current density, voltage-
dependence of activation, recovery from inactivation, or persistent sodium current of NaV1.5 
co-expressed with apo-CaM-F90L compared to apo-WT CaM  (Table 10 & 11).  However, apo-
CaM-F90L shifted in the V1/2 of the voltage-dependence of inactivation -5 mV (-115.0 ± 1.0 
mV) compared to apo-WT CaM (-109.6 ± 1.1 mV) suggesting a loss of steady-state channel 
availability (Figure 37C).  
 To test the calcium-dependent effects of mutant CaM on NaV1.5 function, we repeated 
these experiments with elevated intracellular calcium (~1 µM free Ca+2) to provide a saturating 
concentration to promote binding of CaM to NaV1.5.92,124 Cells co-expressing CaM-F90L with 
NaV1.5 exhibited a 2.2-fold increase in peak current density (-708.9 ± 137.1 pA/pF) compared 
to cells with WT CaM (-315.5 ± 76.4 pA/pF) or apo-WT CaM (-260.2 ± 60.6 pA/pF) (Figure 
37B).  The voltage-dependence of activation of NaV1.5 significantly shifted the V1/2 -7 mV by 
CaM-F90L (-49.7 ± 2.0 mV) compared to WT CaM (42.4 ± 1.8 mV) (Figure 37C). This 
suggests that CaM-F90L in the presence of elevated calcium levels results in a more 
depolarized activation of NaV1.5.  Also in the presence of elevated intracellular calcium, CaM-
F90L still shifted V1/2 of the voltage-dependence of inactivation -5 mV to more hyperpolarized 
potentials (-109.3 ± 2.1 mV) compared to WT CaM (-103.7 ± 1.2 mV) (Figure 37C). Mutant 
CaM-F90L also significantly slows the recovery from inactivation of NaV1.5 (14.6 ± 2.3 msec)  
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compared to WT CaM (11.5 ± 0.8 msec) (Figure 37D). CaM-F90L also elicited similar effects 
on the fetal isoform of NaV1.5 (Table 10). We did not observe any effects of CaM-F90L on 
persistent sodium current in high or low calcium (Table 11).  
 
CDI is slowed by LQTS-CaM  
(The following experiments were performed by researchers at the University of Kentucky in the 
laboratory of John Satin.) 
 We tested the hypothesis that LQTS-CaM mutations with impaired C-domain Ca2+ 
affinity will slow ICaL decay in a native cardiomyocyte environment due to impaired CDI.7 A 
slowing of CDI is one molecular mechanism of LQTS. Figure 38A illustrates representative 
current sweeps normalized to peak current for FVM expressing exogenous WT-CaM 
superimposed on traces from cells expressing each of the LQTS-CaM mutants.  All LQTS-
CaM mutants slow ICaL decay to degrees that match the rank order of Ca2+-CaM affinity (Figure 
38B). Current density and voltage-dependence of current activation were not different between 
FVM expressing WT or LQTS-CaM mutants. These data suggest that attenuated CDI and 
resulting slower ICaL decay contribute to mutant CaM-associated LQTS.   
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Figure 37: CaM-F90L increases current density, shifts voltage-dependence of activation, 
inactivation and slows the recovery from inactivation.  
(A) Representative traces of NaV1.5 co-expressed with WT CaM or CaM-F90L under 
conditions of nominal (apo) and elevated calcium. (B) Current density-voltage relationships 
comparing WT and CaM-F90L effects on NaV1.5 channels (n = 5-8).  (C) Conductance-voltage 
and steady-state voltage dependence of inactivation relationships for NaV1.5 co-expressed 
with WT or CaM-F90L (n = 5-8). Lines represent average fits of the data with Boltzmann 
functions. (D) Recovery from inactivation of NaV1.5 co-expressed with WT or CaM-F90L (n = 
5-8). Biophysical fit parameters for all experiments are provided in Table 10.  
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Table 10: CaM-F90L increases current density, shifts voltage-dependence of activation, 
inactivation and slows the recovery from inactivation under high calcium conditions. 
  
Biophysical Parameters 
Current Density Voltage-Dependence of Activation 
Steady-State 
Availability 
Recovery 
From 
Inactivation 
 
Peak Current 
Density (pA/pF) n V 1/2  (mV) k (mV) n V 1/2  (mV) k (mV) n τ (msec) n 
NaV1.5 + apo-WT CaM -260.2 ± 60.6 5 -40.6 ± 3.7 8.0 ± 0.6 5 -109.6 ± 1.1 -7.9 ± 0.4 5 8.6 ± 0.9 7 
NaV1.5 + apo-CaM-F90L  -314.8 ± 75.6 8 -36.2 ± 1.3 9.2 ± 0.3  
8
  -115.0 ± 1.0 
c -9.0 ± 0.5 8 8.8 ± 0.4 7 
NaV1.5 + WT CaM -315.5 ± 76.4 7 
 
-42.4 ± 1.8 
 
7.9 ± 0.5 7 -103.7 ± 1.2 b -8.8 ± 0.4 7 11.5  ± 0.8 7 
NaV1.5 + CaM-F90L  -708.9 ± 137.1 abc 8 -49.7 ± 2.0 ab 6.2 ± 0.5‡  8 -109.3 ± 2.1 bc -8.1 ± 0.2 8 14.6 ± 2.3 ab 8 
Fetal NaV1.5 + WT CaM -178.4 ± 43.3 7 -43.3 ± 1.7 7.4 ± 0.3 7 -102.7 ± 1.7 -8.9 ± 0.3 8 13.8 ±	  1.7 9 
Fetal NaV1.5 + F90L -820.9 ± 164.9  acd  7  -50.0 ± 3.6	   5.8 ± 0.4 acd  7 -107.8 ± 3.8 -8.5 ± 0.1 8 13.1 ±	  3.0 7 
a P < 0.05 compared to NaV1.5 +apo-WT CaM         
b P < 0.05 compared to NaV1.5 + apo-CaM F90L   
c P < 0.05 compared to NaV1.5 + WT CaM 
d < 0.05 compared to Fetal NaV1.5 + WT CaM 
Table 11: CaM-F90L does not have significant effects on persistent sodium INa. 
 
 Persistent Current % n 
NaV1.5 + WT CaM  0.3 ± 0.1	   9 
NaV1.5 + CaM-F90L 0.3 ± 0.2 5 
Fetal NaV1.5 + WT CaM  0.4 ± 0.1 14 
Fetal NaV1.5 + CaM-F90L 0.2 ± 0.1 7 
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Figure 38: LQTS-CaM mutants slow CDI. 
(A) Representative traces recorded during a depolarization to 0 mV.  The single exponential fit 
of a representative WT-CaM current sweep (dotted line) is illustrated for reference.  The 
smooth line through the current traces is a single exponential fit of the form:  I(t) = Ipeak*e-t/t.  (B) 
Inactivation time constant (t) plotted as a function of voltage.  For clarity, the WT-CaM data are 
illustrated along with each LQTS-CaM mutation plot.  **p<0.01; ****p<10-4. 
 
 
 
 
 114	  
Discussion 
 The major new finding of this study is that CaM mutants associated with LQTS cause 
significantly slowed CDI of ICaL that may alter Ca2+ homeostasis in fetal ventricular 
cardiomyocytes. We also excluded a major contribution of dysregulated sodium current caused 
by LQTS-CaM mutations. We can conclude that LQTS-CaM uses the novel mechanism of 
slowing of CDI to initiate the sequence of cellular physiological events leading to ventricular 
arrhythmia. 
 Fetal sodium channel dysfunction evoked by CaM-D130G under high calcium 
conditions suggests a unique interaction of mutant calmodulin with the fetal splice variant of 
NaV1.5 that is calcium dependent. In addition, this effect is not due to CAMKII phosphorylation 
of NaV1.5. However, there was not a persistent sodium current evoked by CaM-D130G in 
native fetal mouse cardiomyocytes that express fetal NaV1.5 (Figure 31).88 This may be an 
effect unique to the human fetal sodium channels or the expression of mouse fetal NaV1.5 at 
that time in development. We cannot rule out speculation that under high calcium conditions 
that occur physiologically in the myocyte or under some pathological conditions,136,137 there 
may be an aberrant interaction of mutant calmodulin with fetal NaV1.5 that evokes persistent 
sodium currents in addition to the loss of CDI of L-type calcium channels. We speculate that 
the human fetal NaV1.5 may also exhibit some allosteric effects on CaM-D130G that contribute 
to this unique effect. Further studies in human iPS-derived cardiomyocytes from these patients 
may provide further insight to the effects of CaM-D130G on human fetal NaV1.5. 
 Although CaM mutations associated with LQTS did not have a consistent effect on 
sodium channel function, we show that a CaM mutant associated with idiopathic VT evokes a 
gain of function of NaV1.5 under high calcium conditions (Figure 37). In addition, CaM-F90L 
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does not have any significant effects on the CDI of L-type calcium channels (data not shown). 
This suggests that NaV1.5 may be involved in the molecular mechanisms of other arrhythmias 
associated with mutant CaMs. However, future studies in native cardiomyocytes will provide 
further insight on these effects.  
 The studies investigating mutant CaM effects on L-type calcium channel (LTCC) 
function show a rank-order relationship between Ca2+-CaM affinity and the propensity for 
abnormal Ca2+ homeostasis. This relationship holds for the three tested LQTS-CaM mutants.  
LQTS is driven by a prolongation of the ventricular cellular action potential duration (APD), and 
APD is determined by the sum of ionic conductances, principally, net voltage-gated potassium 
channels and LTCC. CaM pre-bound to LTCC confers a direct relationship between CaM 
alterations of LTCC current and APD whereby increased Ca2+ influx prolongs APD.4 The 
LQTS-CaM mutations studied occurred de novo within the carboxyl-terminus (C-lobe) of 
CaM.92 The C-lobe of LTCC-bound CaM senses Ca2+-entry through single LTCC channel 
openings and this occurs in a restricted space where local [Ca2+] can reach levels as high as 
60-100 µM.138,139 The LQTS-CaM mutation F142L C-lobe Ca2+-affinity Kd is 15 µM; well below 
the estimated local [Ca2+] and thus may explain the relatively subtle effects observed with 
F142L. The D130G Ca2+ Kd is 150 µM that is consistent with a greater propensity to promote 
pathological Ca2+ transients among the LQTS-CaM mutants tested. Overall, LQTS-CaM slows 
Ca2+-dependent inactivation of LTCCs (Figure 38) and further explains the pathogenesis of 
LQTS in these cases.   
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CONCLUSIONS 
 
 
 Here we conclude that the voltage-gated cardiac sodium channel is not consistently 
involved in the molecular mechanisms of LQTS associated with mutations in calmodulin. 
However, aberrant mutant CaM function that is calcium dependent may occur in some cases, 
such as in idiopathic VT, that results in sodium channel dysfunction. We also conclude that 
LQTS-CaM uses the novel mechanism of slowing of CDI to initiate the sequence of cellular 
physiological events leading to ventricular arrhythmia. In summary, LQTS-CaM mutations both 
disrupt calcium homeostasis in murine cardiomyocytes but there is a sharp dichotomy in 
pathways leading to pathological phenotypes. LQTS-CaM mutations occurring on the C-lobe of 
CaM reduce Ca2+-affinity and consequently cause slowing of LTCC kinetics by attenuating 
CDI. These results suggest a potential proof-of-principle for genotype-specific treatment of 
“calmodulinopathies.” 
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CHAPTER V 
 
Summary & Future Directions 
 
SUMMARY 
   
  Mutations in SCN5A encoding the cardiac voltage-gated sodium channel (NaV1.5) can 
result in severe life-threatening cardiac arrhythmias such as long QT syndrome (LQTS). 
However, the molecular basis for arrhythmia susceptibility in early developmental stages were 
previously unknown. Although many SCN5A mutations associated with SIDS or perinatal 
LQTS have been investigated in the canonical adult NaV1.5, the molecular factors that 
predisposed to the early onset and severity of these arrhythmias were still unknown. Therefore 
we considered an alternative splicing mechanism of the cardiac sodium channel and proteins 
that interact with cardiac ion channels as molecular factors that may contribute to sudden 
death risk in early life.  
  Here we have presented the molecular mechanisms of SCN5A mutations and 
calmodulin mutations associated with perinatal LQTS in the context of a fetal-expressed splice 
variant of the voltage-gated cardiac sodium channel, fetal NaV1.5. These studies are important 
for determining the molecular mechanism for severe arrhythmias that manifest in the earliest 
stages of development. We hypothesized that fetal NaV1.5 would provide a sensitive 
background for mutations that have been associated with increased arrhythmia susceptibility 
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and sudden death during early life. Our findings demonstrate an important contribution of 
developmentally regulated alternative SCN5A splicing to the genetic risk for prenatal life-
threatening cardiac arrhythmias. We have shown that the SCN5A mutations associated with 
perinatal forms of LQTS (L409P/R558, R1623Q, F1473C and A1330D) exhibit more severe or 
similar functional consequences in the fetal NaV1.5 compared to their expression in the 
canonical adult sodium channel (Chapter II and III). In addition, we have shown that a more 
typical onset LQT3 mutation, delKPQ, exhibits an attenuated gain of function in the fetal 
NaV1.5 compared to expression of the mutation in the adult NaV1.5 (Chapter III). These results 
support the hypothesis that fetal NaV1.5 may mask the effects of a typical onset LQT3 
mutation. Therefore, fetal NaV1.5 is a distinguishing factor in the presentation of LQT3 in these 
cases.  
  We also concluded that the voltage-gated cardiac sodium channel is not consistently 
involved in the molecular mechanisms of LQTS associated with mutations in calmodulin. 
Furthermore, it is the slowing of L-type calcium channel (CaV1.2) Ca2+-dependent inactivation 
(CDI) that may promote arrythmogenesis in calmodulinopathies associated with LQTS 
(Chapter IV). These findings are important for the genotype-specific treatment of severe 
arrhythmias associated with calmodulin mutations.  
  Taken together we present a novel mechanism in the pathogenesis of cardiac 
arrhythmias associated with a severe and early onset of LQTS. This is also important for the 
appropriate treatment of these arrhythmias. Currently, fetal LQTS is treated by infusion of 
lidocaine, a sodium channel blocker. However, we have shown that lidocaine may be an 
ineffective treatment option in some cases of fetal LQTS such as for fetal NaV1.5-L409P/R558 
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(Chapter II). Further experiments are required to determine whether the fetal NaV1.5 exhibits 
an altered pharmacology in the presence of lidocaine compared to the adult NaV1.5.  
  Further treatment options such as gene therapy or more selective channel blockers 
need to be explored for cases of fetal LQTS because treatment options are currently very 
limited. The majority of patients with neonatal LQTS are treated with implantable cardioverter 
defibrillators (ICD) after birth. ICDs use electrical pulses or shocks to treat life-threatening 
arrhythmias that occur in the ventricles. These devices have been shown to be beneficial in the 
long term for patients with severe forms of LQTS.98,140,141 However, further research is required 
to determine the appropriate shock required to terminate fibrillation at the lowest energy to 
prevent severe tissue damage or inappropriate shocks.142 It is very important to improve our 
understanding of the molecular mechanisms of cardiac arrhythmias so that patients can be 
treated appropriately.  
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FUTURE DIRECTIONS 
   
  The majority of the experiments shown in Chapters II-IV involve a heterologous 
expression system to express the fetal or adult NaV1.5 in order to study specific functional 
effects of SCN5A or calmodulin mutations. While this is an appropriate method to elucidate the 
molecular mechanism of sodium channel dysfunction, further experiments are required to 
determine if these effects are pathological in the human heart. One simple approach would be 
to use a mathematical model with the persistent sodium currents measured from cells 
expressing WT or mutant sodium channels as an input to determine the effects on the human 
action potential. However, these models do not provide the concrete evidence needed to 
establish the mechanism of the arrhythmia.  
  It is more favorable to utilize an animal model such as the rabbit to determine if the 
persistent sodium currents evoked by SCN5A mutations result in abnormal action potential 
morphology compared to expression of WT channels. However, this approach poses a difficult 
technical problem of silencing or pharmacologically inhibiting the rabbit endogenous sodium 
currents while virally transducing the mutant or WT human sodium channels into isolated 
ventricular myocytes. Multiple approaches have been tested in our laboratory such as 
adenovirus, lentivirus, and biolistics but these approaches have been unsuccessful with 
sodium channel expression. Furthermore, there is heterogeneity of the ventricular action 
potential among animal models due to the variation in expression of ionic currents.8,12,143,144 
  Another approach to determine the effects of SCN5A mutations on action potential 
morphology would be to utilize human induced pluripotent stem cell derived-cardiomyocytes 
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(iPSC-CMs) to elucidate the molecular the mechanism of the arrhythmia.21,145–147 However, this 
approach requires the consent of the patient or the patient’s family to obtain the skin 
fibroblasts. Once the fibroblasts are obtained, they must be reprogrammed to a pluripotent 
state using viral vectors.148,148,149 When the cells reach a state of pluripotency, they are coaxed 
to differentiate into cardiomyocytes.146 The entire process can take up to several months.145,150 
The advantage of using these cells as a model is that they can recapitulate the disease 
phenotype of the patient such as prolonged action potentials from a patient with LQTS.21,147  
  Unfortunately, there are disadvantages to the use of iPSC-CMs because they are not 
mature cardiomyocytes. They cannot be differentiated into pure populations of ventricular or 
atrial cardiomyocytes.145,146 It is still a technical challenge to sort iPSC-CMs based upon action 
potential morphology alone.21,146 In addition, many factors may contribute to the variation and 
maturity of atrial, nodal, and ventricular-like action potentials including cardiomyocyte 
differentiation protocols, culture conditions of differentiated cardiomyocytes, and recording 
procedures.146 Future work in the field is focused on investigating the molecular determinants 
involved in producing pure populations of cardiomyocytes and nodal cells.151  
  Our laboratory has demonstrated prominent expression of the alternatively spliced fetal 
NaV1.5 mRNA transcript using RT-PCR in fetal and infant human heart.52 We used the same 
assay to investigate the ratio of fetal to adult NaV1.5 transcripts in iPSC-CMs 30 days post-
induction. We observed that the fetal:adult ratio of mRNA transcript was 33.1 indicating 
predominant expression of the fetal splice variant in these cells. These data indicated that 
iPSC-CMs mainly express fetal NaV1.5 at 30 days and 90 days post-induction. Further work 
was proposed to investigate the time-dependence of alternative splicing in iPSC-CMs and to 
establish correlations with channel function. However, a more mature population of cells is 
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required for these studies based on our preliminary findings that the fetal NaV1.5 is primarily 
expressed in these cells.  
  In addition to changing the model to study the unique functional effects of fetal NaV1.5, 
we must also consider that fetal NaV1.5 may exhibit an altered pharmacology in response to 
sodium channel blockers such as lidocaine. Lidocaine is a class Ib anti-arrhythmic used in the 
treatment of ventricular arrhythmias. The mechanism of action of lidocaine on NaV1.5 in the 
open and inactivated states promotes shortening of the cardiac action potential duration.  
Lidocaine has been administered to pregnant women whose fetuses exhibit ventricular rhythm 
disturbances and is a tolerable treatment at an early developmental stage.152 In Chapter II we 
show that fetal NaV1.5-L409P/R558 is resistant to lidocaine treatment suggesting this 
treatment may be ineffective in some cases of fetal LQTS.  
  Previous studies were preformed in our laboratory on the pharmacology of a splice 
variant of SCN1A (SCN1A-5N) which is the same conserved splicing event exhibited for fetal 
NaV1.5.84 The splice variant SCN1A-5N exhibited enhanced tonic block and use-dependent 
block by phenytoin and lamotrigine across a range of stimulation frequencies and 
concentrations as well as induced shifts in steady-state inactivation and recovery from fast 
inactivation. These data suggest that the splice variant is more sensitive to commonly used 
anti-epileptic drugs.153 It is likely that the fetal splice variant of NaV1.5 will also exhibit 
differential pharmacological responses to lidocaine or other sodium channel blockers when 
compared to the adult NaV1.5. Another interesting candidate to study the pharmacological 
effects on the fetal NaV1.5 is ranolazine because it has been shown to inhibit persistent sodium 
current.132,154 These studies are required to evaluate the current methods of treatment of fetal 
and neonatal LQTS and to promote the development of new therapeutic strategies. 
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  The remaining question beyond the studies presented in Chapters II-IV, is why the fetal 
heart requires an alternative splicing mechanism of NaV1.5. We speculate that the depolarized 
activation of fetal NaV1.5 may be a protective mechanism for the developmental changes in 
resting membrane potential of fetal cardiomyocytes from more depolarized potentials to 
hyperpolarized potentials. We conceive that this would result in a more depolarized threshold 
of sodium channel activation in the immature heart.10,12,151,155  
  It is also plausible that there is a functional role of fetal NaV1.5 beyond membrane 
depolarization such as in the migration of fetal cardiomyocytes in the developing heart.89 The 
disruption of the mouse cardiac sodium channel gene, Scn5a, causes intrauterine lethality in 
homozygotes with severe defects in ventricular morphogenesis whereas heterozygotes show 
normal survival.156 Fetal NaV1.5 has been shown to be required in the migration of human 
metastatic breast cancer cells (MDA-MB-231). Migrated MDA-MB-231 cells expressed more 
fetal NaV1.5 protein at the plasma membrane than non-migrated cells.89 To become motile and 
invasive, embryonic epithelial cells undergo a process of mesenchymal conversion known as 
epithelial-to-mesenchymal transition (EMT). Likewise, EMT can be seen in cancer cells as they 
leave the primary tumor and disseminate to other parts of the body to colonize distant organs 
and form metastases.157,158 Therefore, the effects of fetal NaV1.5 on MDA-MB-231 cells may 
also provide a similar mechanism in the developing heart.  
  To test whether fetal NaV1.5 has a greater role in the developing heart, future work 
would require the development of a mouse model that only expressed either the adult or fetal 
NaV1.5. For example, a fetal NaV1.5 knockout mouse may reveal an abnormal phenotype that 
would result in further dissection of the function of fetal NaV1.5 in embryonic development, 
cardiac conduction, or ventricular morphogenesis. However, the development of such a mouse 
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model would require further investigation into the mechanism of the alternative splicing event 
and required machinery involved. The mouse fetal NaV1.5 has the same 7 amino acid 
substitutions found in the human fetal NaV1.5 protein sequence (See Chapter I) but differs in 
the DNA sequence by 4 nucleotides, which may be either silent or regulatory. Therefore, a 
mouse model may be a useful experimental tool to investigate the molecular mechanisms of 
cardiac arrhythmias and cardiac development associated with fetal NaV1.5 and provide further 
information on the regulation of the expression of the splice variant.104,159,160  
  In Chapter IV we show that the fetal NaV1.5 is sensitive to a calmodulin mutation, CaM-
D130G that evokes persistent sodium current under high calcium conditions. Although this 
effect was not recapitulated in mouse fetal cardiomyocytes, this suggests that human fetal 
NaV1.5 may exhibit a unique interaction with calmodulin. Further studies investigating the 
calcium sensitivity of fetal NaV1.5 may provide insight to the functional effects of CaM on the 
alternative splice variant compared to the adult isoform of the channel. These experiments 
could be modeled after previous work on the calcium sensitivity of canonical NaV1.5.124,161 
Similar studies investigating the effect of pH changes on fetal NaV1.5 may also provide insight 
to the adaptive electrophysiological response in fetal development.162–166  
  In summary, multiple approaches may be used to further investigate the molecular 
mechanisms of LQTS that manifest in the early stages of life. Future work to improve the 
differentiation of iPSC-CMs or to develop a mouse model to study the role of fetal NaV1.5 in 
development would provide further insight to the mechanism of arrhythmogenesis of early 
onset LQT3. Furthermore, we have used our heterologous expression system (Chapter II-IV) 
to demonstrate an important contribution of developmentally regulated alternative SCN5A 
splicing to the genetic risk for perinatal life-threatening cardiac arrhythmias. These studies 
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were highly important to establish a molecular mechanism in the pathogenesis of LQT3 in the 
earliest stages of development.   
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